Clemson University

TigerPrints
All Dissertations

Dissertations

August 2018

Bacteria-Mediated Delivery of mazF mRNA into Cancer Cells for
Induction of Apoptosis
Maryam Saffarian Abbas Zadeh
Clemson University, msaffar@g.clemson.edu

Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations

Recommended Citation
Saffarian Abbas Zadeh, Maryam, "Bacteria-Mediated Delivery of mazF mRNA into Cancer Cells for
Induction of Apoptosis" (2018). All Dissertations. 2557.
https://tigerprints.clemson.edu/all_dissertations/2557

This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been
accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information,
please contact kokeefe@clemson.edu.

BACTERIA-MEDIATED DELIVERY OF mazF mRNA INTO CANCER CELLS FOR
INDUCTION OF APOPTOSIS

A Dissertation
Presented to
the Graduate School of
Clemson University

In Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy
Microbiology

by
Maryam Saffarian Abbas Zadeh
August 2018

Accepted by:
Dr. Tzuen-Rong Tzeng, Committee Chair
Dr. Min Cao
Dr. Wen Chen
Dr. Yanzhang Wei

ABSTRACT
Programmed cell death (PCD), an active process that leads to cell suicide, is a
critical mechanism in eukaryotes and prokaryotes. In eukaryotes, apoptosis, a wellcharacterized form of PCD, is a gene-directed program that can be inhibited by some
oncogenic mutations, resulting in the development of cancer. Toxin-antitoxin (TA) is one
example of an intracellular death program that is present in almost all bacteria and
comprises a stable toxin and a labile antitoxin that blocks the lethal function of the toxin.
MazEF, one of the best studied bacterial PCD systems, includes a toxin, namely, MazF that
cleaves mRNAs at ACA sequences leading to the inhibition of protein synthesis. Although
the exact mechanism remains unknown, it seems the MazF-mediated apoptosis depends on
the presence of BAK, a pro-apoptotic protein in mammalian cells. Since cancer is a
heterogeneous group of diseases with various sensitivities to different treatments, we
examined the impact of MazF proteins on the growth and viability of three cancer cell
lines: MCF7, HT29, and AGS. These cells lines were transfected with ACA-less mazF
mRNAs, and the cells were evaluated for development of MazF-mediated cell death. Our
data illustrated that expression of MazF proteins in the aforementioned cells leads to
significant reductions in cell viability. In order to confirm the occurrence of apoptosis, the
activation of caspase-3 and -7 and the presence of caspase-3’s substrate were evaluated in
transfected cells. Our observations suggested that in the presence of MazF, the levels of
activated caspase-3 and -7 were significantly elevated in transfected cells. In addition, the
inhibition of protein synthesis by MazF in MCF7 and AGS cell lines were examined via
quantifying mRNA translation on a single-cell basis. Our data confirmed that the
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expression of MazF causes a significant drop in the levels of protein translation in the
examined cell lines. Recently, it has been reported that the DNA delivery system does not
seem to be a suitable approach to transfer mazF in tumors due to the lack of continuous
expression of MazF, degradation, and the incidence of mutations in mazF gene. To address
these challenges, we developed an mRNA delivery system to transfer ACA-less mazF
mRNA exclusively into cancer cells. To examine the expression and stability of mazF
mRNA in cells, we synthesized mazF and GFP mRNA for IRES- or cap- dependent
translation. Our results suggest that cap/IRES-dependency, poly-A tails, and
modified/unmodified nucleotides played important roles in efficient expression of MazF
proteins in transfected cell lines but is dependent on the cell line.

MazF is a nonspecific ribonuclease that can induce death in both normal and cancer
cells. Thus, the application of MazF is dependent on efficient expression and delivery
system to transfer MazF into tumors. We developed a listerial bi-vector expression and
delivery system to transfer mazF mRNA into specific HER2-positive SKBR3 human breast
cancer cells. Our results showed that following the infection of cells by functionalized
bacterial vectors, caspase activities elevated in SKBR3 cells 48 hours post-transfection. In
this research, this expression and delivery system for the delivery of mazF mRNA as a
potential therapeutic mRNA in cancer cells was reported for the first time.
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CHAPTER ONE
1.

Literature Review

Hallmark Traits of Cancer and Their Roles in Tumor Growth and
Metastasis
Cancer, as the plague of the current centuries, arises from the abnormal
proliferation of a group of cells that bypass the strict cell division rules. Unlike cancer cells,
normal cells do not have an autonomy to divide, differentiate, or die, and their behaviors
and destinies are dictated by molecular networks and signals. Once mutations or alterations
occur in these stern networks, the balance between cell division and quiescence is
interrupted, and cells are liable to develop a neoplastic state [1].

Cancer is described as a multi-gene, multistep disease stemming from the domino
effect of mutations in cell genomes, promoting the formation of a tumor mass [2].
Consecutively, a series of mutations causes tumor expansion and progression, and
ultimately, tumors disrupt the surrounding tissues of the basal membrane barrier and
metastasize to other tissues or organs [2].

Tumors are complex tissues and contain multiple distinct cells interacting with one
another and with the tumor microenvironments. These cells share several cancerous
biological traits, enabling them to develop tumorigenic and metastatic natures. The
sustainment of proliferative signals, evasion of growth suppressors, resistance to cell death,
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replicative immortality, induction of angiogenesis, activation of invasion and metastasis,
energy metabolism, evasion of immune destruction, genome instability and mutation, and
tumor-promoting inflammation are hallmarks of cancer [3].

The architectures and functions of normal tissues are maintained through the
molecular signaling networks that strictly control the production and availability of growthpromoting signals, while cancer cells have biological capabilities to preserve mitogenic
signaling, resulting in growth and progression of tumors. These capabilities include the
overexpression of growth factor ligands displaying on the surfaces of cancer cells,
stimulation of normal cells to provide various growth factors for cancer cells, and the
induction of independency to growth factors [3].

In addition to stimulating cell proliferation, cancer cells also have the ability to
overcome negative regulation of cell proliferation circumstances. These abilities arise from
the lost or nonfunctional suppressor genes in tumors. The two prototypical tumor
suppressors encoding the RB (retinoblastoma-associated) and TP53 proteins mainly
regulate the balance of cell proliferation or death in normal tissues. In cancer cells, the
nonfunctional RB are unable to critically monitor the cell-cycle progression, which causes
continued cell proliferation in tumors. The TP53 protein senses abnormal intracellular
signals, such as excessive damage to the genome, efficiency of glucose, oxygenation, or
nucleotide pools. Consequently, TP53 temporary blocks the cell-cycle progression during
these abnormal conditions. In addition, this protein can recognize the overwhelming or
irreparable damages to cellular systems and induce apoptosis in normal cells. However,
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cancer cells with nonfunctional TP53 genes are unable to receive intercellular signals and
suppress cell proliferation [3].

Resistance to cell death is another hallmark of cancer cells. Apoptosis, as a form of
programmed cell death, serves as the main barrier to uncontrolled cell proliferation in
normal cells. The occurrence of apoptosis is regulated by counterbalancing pro- and antiapoptotic members of the Bcl-2 family. In cancer cells, this balance is disturbed, and
proapoptotic proteins stimulate the hyperproliferation in tumors [4].

Normal cell proliferation is limited and is governed by two distinct phases:
senescence, the state of cells being non-proliferative but viable, and crisis, the cell death
state. Subsequent to repeated cycles of division, cells enter a senescence phase during
which the proliferation of live cells is halted, and then death is induced in the majority of
cells. However, cancer cells develop an immortal nature in which cells escape either
senescence or crisis and continuously proliferate. The immortality ability might stem from
the telomeres protecting the ends of chromosomes in cells. In normal cells, telomerase,
hexanucleotide repeats, protect the ends of the chromosomes to enhance the stability of
chromosomal DNA but shorten progressively during cell divisions. Thus, cell division is
tightly linked to the length of telomeric DNA, and once these telomeres are eliminated, the
crisis phase is triggered. In contrast to normal cells, cancer cells overexpress telomerase,
the specialized DNA polymerase adding telomere repeat segments to the ends of telomeric
DNA, and stabilize their chromosomal DNA, leading to the development of resistance to
both senescence and crisis/apoptosis [3].
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One of the important hallmarks of cancer tumors is their abilities to promote
angiogenesis. Both normal tissues and tumors need to have access to nutrients and oxygen
and clear their wastes and carbon dioxide. Angiogenesis is defined as the development and
remodeling of new blood vessels to supply oxygen and nutrients and evacuate metabolic
wastes from tissue environments. In normal tissues, normal vasculature is quiescent, but in
adults, during physiological processes, angiogenesis can be transiently activated and
induce formation of new vessels. However, this pathway continuously generates and
remodels blood vessels in cancer cells [5]. In normal cells, vasculature contains organized
and differentiated networks of arteries, arterioles, capillaries, venules, and veins. In tumors,
vasculature systems are remodeled and consist of irregular, abnormal, and large blood
vessels which cannot supply sufficient nutrients or oxygen for tumors. This system is also
deficient in evacuating carbon dioxide and other metabolites, leading to the creation of an
acidic tumor microenvironment. The vasculature systems also play an important role in the
formation of metabolic insufficiency, ischemia, and necrotic zones in each tumor.
Hyperpermeability, another trait of tumor vasculature systems, causes the occurrence of
local edema and extravascular clotting of plasma in tumors and affects the gene expression
patterns in fibroblasts and endothelial cells [2].

In cancer cells, angiogenesis pathways are regulated by several signals, such as the
secretion of growth factors and cytokines from tumors and the tumor microenvironment
[2]. For example, vascular endothelial growth factor-A (VEGF-A) and thrombo-spondin1 (TSP-1) are cell surface receptors that regulate the stimulation and inhibition of
neovascularization, respectively [3]. In cancer cells, various factors, such as activation of
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oncogenes, loss of tumor suppressor genes, hormones, and other cytokines are involved in
the overexpression of VEGF-A in tumor cells [2] .

One of the most notable hallmarks of cancer tumors is their ability to invade and
metastasize to other sites. The local spread of highly pathological epithelial cells is referred
to as cancer invasion, while distant migration of cancer cells is called metastasis, which is
the most common reason for mortality in cancer patients. Generally, it has been observed
that cancer cells involved in invasion or metastasis processes lose E-cadherin cell-to-cell
adhesion molecules which affect the attachment of cancer cells to other epithelial cells and
to the extracellular matrix (ECM). Cancer cells usually downregulate the expression of Ecadherin or possess a mutant and nonfunctional form of this protein. In addition to Ecadherin, the gene expression of other adhesion molecules is also downregulated, but other
molecules involved in cell migration, such as N-cadherin, are upregulated in cancer [3].

Invasion and metastasis are known as the multistage processes and invasion
abilities that some of the cells develop to attack the regional sites. These cells then invade
nearby blood and lymphatic vessels and transfer to the parenchyma of distant tissues. The
migrated cells colonize and establish small nodules (micrometastases) in the new sites.
Eventually, the micrometastases expand and form macroscopic tumors. However, the exact
mechanisms of invasion and metastasis remain to be discovered [6].

The heterogenic nature of cancer has been the main barrier to fighting cancer. The
hallmark traits of tumors led to the advent of hallmark-targeting cancer drugs in cancer
therapy. These targeting therapeutics can block one or more capabilities of tumors at
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molecular levels and hinder tumor proliferation and expansion. The target specificity and
safety profiles of these drugs have been attractive enough to lead to the development of
experimental and clinical trials in exploiting cancer hallmarks to destroy tumors. However,
several challenges, such as the development of adaptive resistance through mutation,
epigenetic reprogramming, remodeling of the stromal microenvironment, and the presence
of parallel signaling pathways for each capability, have minimized the advantages of the
treatments [3].

Apoptosis: Events and Pathways in Normal Cells
Programmed cell death (PCD) is defined as the occurrence of cell death by an
intracellular mechanism [7]. According to the Nomenclature Committee on Cell Death
(NCCD), PCD can be categorized into different distinct modalities based on changes on
cell morphology (apoptosis, necrosis, or autophagy), enzymological activities (activation
or inactivation of nucleases or proteases, such as caspases, calpains, cathepsins, and
transglutaminases), functional criteria (programmed or accidental, physiological or
pathological), or immunological features (immunogenic or nonimmunogenic) [8].

The term apoptosis was coined by Kerr, Wyllie, and Currie in 1972 to describe the
morphological events involved in a type of cell death [8]. Apoptosis is a tightly regulated,
multistep programmed cell death that secure embryogenesis and tissue homeostasis and
eliminate damaged or infected cells. Cells undergoing apoptosis develop several
morphological and biological changes such as cell shrinkage, DNA fragmentation
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(karyorrhexis),

chromatin

condensation,

phosphatidylserine

externalization,

encompassment of the cell contents in small vesicles, and then the separation of vesicles
from the adjacent or extracellular matrix. The formed vesicles will be eventually engulfed
by other cells. Apoptotic cells share several biochemical alterations such as protein
cleavage,

protein

cross-linking,

DNA

breakdown,

mitochondrial-membrane

permeabilization (MMP) and/or massive caspase activation [4].

Apoptosis is a sophisticated process which occurs through two main pathways: the
extrinsic (or death-receptor) pathway and the intrinsic (mitochondrial) pathway. In both
pathways, a family of endoproteases, caspases, provide critical links in cell regulatory
networks and cell death [9]. However, the two pathways are not synchronized. Caspases
are a group of proteinases that degrade proteins at aspartic acid residues and promote the
irreversible death in apoptotic cells. Based on their activities, these proteinases are
classified into three groups: initiators (caspase 2, 8, 9, and 10), effectors or executioners
(caspase 3, 6 and 7), and inflammatory caspases (caspase 1, 4, and 5). Also, there are other
caspases present in cells that are active at certain conditions, such as caspase 11, which
induces apoptosis during septic shock; caspase 12, which involved in endoplasmic-specific
apoptosis and cytotoxicity by amyloid-β; caspase 13, which is a bovine gene; and caspase
14, which participates in embryonic tissues [10].

In the extrinsic pathway, the activated plasma-membrane receptors, as members of
the tumor necrosis factor (TNF) receptor superfamily, transmit a death signal from the cell
surface to the intracellular signaling pathways that lead to the activation of caspase 8 and
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trigger the execution phase of apoptosis [9]. TNF receptors possess two domains, the
cysteine-rich extracellular and the cytoplasmic (death domain, DD) domains, which are
common among all the dead receptors. The cytoplasmic domains are responsible for
delivering the external signals to intracellular signaling pathways and triggering apoptosis.
The extrinsic pathways are generally activated through the interaction of ligands and
receptors. FasL/FasR, TNF-α/TNFR1, Apo3L/DR3, Apo2L/DR4, and Apo2L/DR5 are
well-known examples of ligand-receptor reactions involved in apoptosis. In this pathway,
once ligands bind to their cognate receptors, cytoplasmic adapter proteins in cells bind to
the cytoplasmic domains of receptors and activate caspase 8 inside cells [10].

In comparison to the extrinsic pathway, the highly complex intrinsic (stress)
pathway is involved in mitochondrial-initiated events, which comprise various sets of nonreceptor-mediated stimuli and intracellular signals [9]. In this pathway, the proapoptotic
members of the Bcl2-family, BAX and BAK, influence the permeabilization of
mitochondria by creating pores in the outer mitochondrial membrane (OMM) and release
two groups of potentially lethal proteins. The first group contains cytochrome c,
Smac/DIABLO, and the serine protease HtrA2/Omi. These proteins are involved in
caspase-dependent pathways. The release of cytochrome c in the cytosol leads to the
activation of the caspase adaptor Apaf-1 and procaspase-9, which together form a
holoenzyme complex named the apoptosome. Caspase 9 possesses holoenzymes that
activate caspase 3 and caspase 8 and eventually induces apoptosis in cells [11].
Smac/DIABLO and HtrA2/Omi have affinities to interact with IAP (inhibitors of apoptosis
proteins) activity and stimulate apoptosis [12]. AIF, endonuclease G, and CAD are the
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second group of proteins released from mitochondria. These proteins translocate to the
nucleus and mediate DNA fragmentation, condensation of peripheral nuclear chromatin,
and production of oligonucleosomal DNA fragments in the nucleus [13]. AIF and
endonuclease G activities are caspase-independent, while CAD cleaves the DNA fragments
generated by caspase 3 and provokes more chromatin condensation in nuclei [14].

The Bcl-2 family plays vital roles in regulation of intrinsic pathways. Bcl-2 proteins
are categorized into 3 groups: the anti-apoptotic subfamily (Bcl-2, Bcl-xL, Bcl-w, Mcl-1,
A1, and also Bcl-B in humans), the apoptotic family, and BH3-only proteins (BID, BIM,
PUMA). The anti-apoptotic proteins have homology in (BH) 1, 2, 3, or 4 domains, while
pro-apoptotic BH3-only proteins possess homology in the BH3 domain. Based on their
functions, the apoptotic proteins can also be classified into two groups: activator BH3-only
proteins (BID, BIM, PUMA) and effectors (BAX and/or BAK proteins). The interaction
between these two groups of proteins leads to the formation of pores in mitochondrial
membranes, which triggers apoptosis cascades. Anti-apoptotic Bcl-2 family members
block the interaction of activators and effectors (BAX and BAK) or directly bind to
activated BAX and BAK and halt the apoptosis incidence. On the other hand, “sensitizer”
BH3 proteins (e.g., BAD, NOXA, etc.) can shift the balance toward apoptosis by binding
to anti-apoptotic proteins and release activators. Overall, the pro- and anti-apoptotic Bcl-2
proteins tightly regulate the mitochondrial apoptotic response based on the stage of cell
growth and the necessity of cell eliminations [15].
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Apoptosis Inhibitors in Tumors
Apoptosis, a gene-directed program, can be inhibited by some oncogenic
mutations. Also, these mutations can promote tumor initiation. For example, the Fac/DC95
receptor regulates cell numbers by inducing apoptosis in the extrinsic pathway; disruption
of this pathway can cause lymphoproliferative disorders and even cancer [16].

The Bcl-2 family is known as the key regulator of the intrinsic pathway. Bcl-2, as
an anti-apoptotic protein, is over-expressed in many types of cancer cells, such as renal,
stomach, and brain cancer. In cancer cells, various alterations and mutations, such as
chromosomal translocations, gene amplification, increased gene transcription, altered posttranslational processing, transcriptional activation by NF-B signaling, or promoter hypomethylation, might provoke the overexpression of Bcl-2 proteins [15]. The overproduced
Bcl-2 proteins play important roles in multiple processes, such as tumor progression,
invasion, and tumor adaptations to chemotherapeutic drugs and radiation therapy [17, 18].
Numerous studies on transgenic mice have exhibited that the overexpression of Bcl-2, BclxL, or Mcl-1 proteins determine the expansion, maintenance, and survival of cells in
established tumors [19], while the deletion of Bcl-2 proteins on a transgenic mouse
leukemia model was reported to abolish leukemic cells in surviving mice [20]. Another
anti-apoptotic protein, XIAP, is a caspase inhibitor overexpressed in breast, colon, and
pancreatic cancers. The downregulation of XIAP can promote the execution phase of
apoptosis in cancer cells [21].
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Downregulation of proapoptotic Bcl-2 proteins is another factor that stimulates
tumor formation and progression. Animal model studies have revealed that suppressed,
post-translational modifications or deficient BH3-only proteins have a permissive
influence in the tumorigenesis process. In addition, BAD and BIM deficient also facilitate
the development of lymphoma in transgenic mice [22].

In normal cells, the tumor suppressor p53 is one of the key proteins that reacts to
apoptotic stimuli and triggers apoptosis through upregulation of pro-apoptotic genes,
including PUMA, NOXA, BID, and BAX. The elimination of p53 or the presence of TP53,
a mutant form of p53, disturbs the balance of apoptotic and anti-apoptotic proteins, which
leads to the inhibition of apoptosis, promotion of cell proliferation, and stimulation of
tumor progression [22].

Overall, the inhibition of apoptosis pathways plays a vital role in the initiation,
growth, and invasion of cancer tumors. Recognition of apoptosis stimuli and inhibitors
could be the key to innovative therapeutic approaches.

Programmed Cell Death in Bacteria
Programmed cell death is not limited to eukaryotic cells. Bacteria are usually
exposed to harsh conditions such as amino-acid starvation, antibiotics treatment,
temperature change, DNA damage, and phage contamination. Hence, regulation of cell
growth and death is crucial for bacterial populations [23]. As mentioned above,
programmed cell death (PCD) is defined as any form of death caused by an intracellular
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death program [23]. Toxin-antitoxin (TA) is one example of an intracellular death program
that is present in almost all bacteria and comprises unsensational bicistronic operons
containing toxins and antitoxin [24]. In TA systems, toxins target several processes such
as DNA replication, mRNA stability, protein synthesis, and ATP synthesis, while their
cognate antitoxins prevent toxin activities during the normal condition [25].

In all TA systems, toxins are seen as small stable proteins, while antitoxins are
labile and have different structures. Based on the nature and functions of the antitoxin, TA
systems have been categorized into five groups (I-V) [26]: The Type I TA system includes
antisense sRNAs as antitoxins, which are located at the upstream of toxin genes with the
reverse orientation. In this system, the antitoxin binds to the toxin mRNA and impedes the
translation of the toxin [26]. In turn, the unleashed toxin creates a pore in the bacterial inner
membrane and disturbs ATP synthesis [25].

In a Type II system, both antitoxins and toxins are small proteins encoded on the
same operon. At normal conditions, the antitoxin binds to the toxin and precludes toxin
functions. Under stressful environmental conditions, the toxin is released from the stable
antitoxin-toxin complex, and the antitoxin is degraded by ATP-dependent proteases [25].

The Type III system was initially reported from Erwinia carotovora sub-species
atrosepticum (Pectobacterium carotovoum). In this system, an sRNA, as the antitoxin,
interacts with the toxin protein and blocks its functions [25].
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Recently, two other TA systems have been discovered in E. coli [25]. The Type IV
TA system was named yeeU/yeeV (ctbA/ctbB), wherein the antitoxin, yeeU, does not bind
to the toxin, but instead hampers the toxin’s function by stabilizing the toxin’s targets. In
this system, the toxin binds to two important cytoskeleton proteins, MreB and FtsZ, and
inhibits the cytoskeleton assembly process and cell division [27].

The Type V system has been classified as the ghoS/ghoT TA system, which
involves GhoS, which digests the toxin mRNA, blocking its translation [28].

MazEF: Type II Toxin-Antitoxin
MazEF is a well-studied TA system that possesses all the common features of the
Type II system. In this system, an unstable antitoxin protein (MazE) antagonizes the stable
toxin’s (MazF) function under normal conditions. Both MazF and MazE are co-expressed
proteins and located downstream of the relA gene [29]. MazE autoregulates the
transcription of the TA operon [30].

The MazEF system is present on chromosomes of many bacteria, such as E. coli,
Myxococcus xanthus [31], and Bacillus subtilis [32]. However, the toxin recognizes
different cleavage sites on mRNA in various bacteria. For example, E. coli MazF cleaves
^ACA, while M. xanthus MazF digests GU^UGC [25].

MazEF, a stress-induced death-mediated system [33], is triggered by several harsh
conditions, such as extreme amino acid starvation, blocked transcription or translation by

13

antibiotics (e.g., rifampin, chloramphenicol, and spectinomycin), high temperature, DNA
damage caused by thymine starvation, mitomycin C, nalidixic acid, and UV irradiation
[34].

One of the most interesting aspects of the mazEF system is the mode of action.
Several investigations have indicated that ectopic overexpression of MazF blocks protein
translation in bacteria but does not affect DNA or RNA synthesis. The MazF protein has
several targets, including specific sites in single-stranded mRNAs, tmRNA, tRNA-mRNA
hybrids that bind to the A site of ribosomes, and 16S rRNA in bacteria [23, 29, 35, 36].
Zhang et al. shed light on the MazF enzymatic function by studying DNA-RNA chimeric
substrates containing an XACA sequence. Their research has revealed that MazF cleaves
RNAs at either the 5´or 3´ of the first A residue of the ACA sequences. MazF cleaves
phosphodiester bonds at the 5´ side, leading to the formation of a free 5´-OH group on the
3´-end cleavage product and a 2´, 3´-cyclic phosphate on the 5´-end product. The OH group
at the cleavage site is important for MazF function, making it comparable to the function
of RNase A in the cleavage of RNA. Thus, because of its function, MazF is known as an
RNA restriction enzyme [37].

The Application of MazF in Biotechnology
The ribonuclease activity of MazF has opened new doors for many applications in
biotechnology. The single protein production (SPP) that utilizes MazF is particularly
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valuable in protein structure biology. With the SPP technique, the gene of interest is
engineered to be an ACA-less sequence without altering the amino-acid sequence. While
MazF proceeds to cleave almost all of the bacterial mRNA, the protein of interest is
produced in the cells. In other words, overexpression of MazF turns E. coli cells into “a
single protein production” factory [38].

Shimazue and colleagues have shown that MazF is capable of impeding protein
synthesis and inducing Bak-dependent apoptosis in mammalian cells [39]. This finding has
brought about an intriguing application for the use of MazF against human viruses such as
HIV. This virus requires the Tat protein (transactivator of transcription) and TAR
(transactivation response) to induce the transcription of the HIV-1 genome. Chono et al.
developed a Tat-dependent production of a MazF construct to eliminate cells harbouring
HIV [40]. In this system, mazF is inserted downstream of HIV-1 U3-TAR and is solely
induced in infected cells. Therefore, the MazF protein cleaves the viral mRNA from HIV1 IIIB to completely inhibit viral proliferation in the cells [40]. The Hepatitis C virus (HCV)
is another virus that could be eliminated by MazF. This virus requires NS3 serine protease
in order to replicate inside the host cells. Shapira et al. designed an interesting construct
that includes mazF linked with mazE via an NS3-cleavable linker. The MazF proteins
produced by the construct will be unleashed and thus induce apoptosis in infected cells at
low levels of NS3 [41]. Based on this previous research, we hypothesized that mazF gene
could be a useful candidate for induction of apoptosis in cancer cells. Moreover, one
objective was to employ bacteria as smart vectors in order to limit MazF protein toxicity
to cancer cells but not to healthy cells.
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Bacterial Delivery Systems
The idea of recruiting bacteria against tumors was conceived over 200 years ago
when Dr. Busch demonstrated that Streptococcus pyrogenes can colonize the late stage of
sarcoma tumors and cause primary tumors and lymph node shrinkages within a week.
However, the lethal impacts of the bacterial infection prevented bacterial-based treatment
from being further pursued. Thirty years later in 1891, Dr. Coley observed that the
inoculation of several inoperable tumors with Streptococcus pyrogenes was not completely
effective to stop tumor regression. Thus, Coley developed a toxin containing heat-killed
microorganisms – S. pyogenes and Serratia marcescens –against lymphoma and sarcosma
and named it Coley’s toxin [42]. In 1976, for the first time, a bacterial toxin was used in
clinical trials against cancer. Morales, Eidinger, and Bruce showed that the Bacillus
Calmette-Guérin (BCG) vaccine has an immunotherapeutic effect on urinary bladder
cancer. The vaccine is still applied for treatment of high-risk urinary bladder tumors [43].
Over the past decades, accumulated knowledge and technological advances have led to
overcoming obstacles with bacterial therapy, such as low efficiency but high toxicities, and
development of various applications utilizing bacteria for the treatment of bacteria against
cancer.

The preference of bacteria to colonize and replicate in tumors has prompted the
emerging interests of utilizing bacteria in cancer therapy. Although the exact mechanism
of colonization remains to be discovered, the natural ability of bacteria to sense a tumor
environment might stem from some tumor features such as abundant of secreted nutrients
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in the microenvironment, the presence of hypoxia, and the leaky vascular systems in tumors
[44]. This preferential tumor accumulation has been reported for various bacteria genera
such as Salmonella, Escherichia, Clostridium, Bifiobacterium, Listeria, Shigella, Vibro,
and Staphylococcus [45].

Bacteria and Tumor Microenvironments
The current knowledge in cancer therapy has revealed that the heterogenic nature
of tumors and their microenvironments contribute to progression, invasion, and metastasis
and determine the success of treatments to defeat tumor growth. Aggressive tumors have
extraordinarily high proliferation abilities, which leads to creating unorganized vascular
systems and regions with a low concentration of oxygen in contents but are highly acidic
in nature and possess accumulated waste metabolites. These regions develop an
immunological self-tolerance area. These environments are ideal for abnormal tumor cells
and cause them to be more resistant to radiation, anticancer chemotherapy, or normal
apoptotic mechanisms [44]. Hypoxia, the area with low oxygen concentration, is one of the
main obstacles in the usage of traditional therapies such as chemotherapy and radiotherapy.
Hypoxia can provoke the induction of various transcription factors such as the hypoxia
inducible factor 1(HIF1), resulting in the induction of the vascular endothelial growth
factor (VEGF) and stimulating the angiogenesis process in tumors [44, 46]. Therefore,
hypoxia has always been an attractive target to attack in tumors. Due to the lack of a low
concentration of oxygen, necrotic zones and hypoxia are desired areas for various
anaerobic and facultative bacteria to colonize or escape from immune systems [44, 47].
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In addition to hypoxia, the secretion of chemotaxins and nutrients, e.g., purines,
and the permeable nature of tumor vascular systems are other attractive elements to direct
bacteria toward tumors. Ye et al. reported that bacterial tumor colonization is a dosedependent process, with a threshold of 104 and 105 cells to prevent the clearance of bacteria
by the immune system. In addition, there is no correlation observed between bacterial
tumor colonization and some bacterial features such as gram morphology and
pathogenicity or tumor characters, e.g. tumor growth rate or tumor volume. In contrast, the
stages of tumor development and the presence of necrotic areas stimulate bacterial
colonization in tumors [44]. In addition, the immune-privileged nature of tumors and the
presence of nutrients in microenvironments are other factors that make solid tumors and
metastases a desired place for bacterial replication [48].

Together, the nature of tumors, coupled with the ability of bacteria to colonize
tumors, has provided valuable knowledge and tools for targeting cancers.

Bacterial Cancer Therapies
Due to the limitations and side effects of traditional cancer therapies, the advent of
innovated approaches with high specificity has been prioritized over the past decades. In
cancer therapy, the ideal treatments are illustrated with various characteristics such as being
nonpathogenic, nonimmunogenic agents, cost-effective, easy to generate, having high
preferences in targeting tumors and metastasis, and their abilities to deliver or express
therapeutic genes or proteins in tumors. Bacteria, due to their unique capabilities to
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colonize tumors, seem to be a suitable agent in cancer therapy [44, 49-52]. Bacteria are
inclined to localize in tumor microenvironments. For instance, the abundance of aspartate
and ribose in tumor microenvironment makes tumors a preferential home for Salmonella
typhimurium [51]. These tendencies of bacteria to migrate toward tumors have made
bacteria a versatile agent with high safety profiles against tumors. In addition, the motility
of bacteria allows them to travel to various regions of tumors that remain inaccessible for
other treatments. Beyond the natural features, the ease of genetic modifications for many
applications make bacteria good candidates to be superior agents in cancer therapy (Figure
1.1).

Figure 1.1. Motile bacteria can travel throughout tumors [53]. Reproduced with permission from Springer
Nature and Copyright Clearance Center.
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Figure 1.2. Bacteria: Smart vectors to identify tumors [51]. Reproduced with permission from Springer
Nature and Copyright Clearance Center.

Over the past decades, bacteria have been recruited for multiple purposes in cancer
therapies. It has been reported that the Clostridium spores are promising treatments to grow
in and destroy hypoxia, and bacterial toxins can stimulate apoptosis in apoptosis-resistant
tumors [51, 54]. Live, attenuated, and nonpathogenic bacteria can also be utilized to
replicate in tumors and destroy them. Lactobacillus sp., Bifidobacterium sp., and
Streptococcus, as probiotic bacteria, can cure or prevent the regression of bladder cancer
with no side effects on normal cells [55, 56]. Salmonella, facultative bacteria, tend to dwell
in tumors of different sizes. This preference stems from the presence of two promoters
(pflE and ansB promoter regions) in Salmonella’s genome, which, once activated in
hypoxia, facilitate bacterial reproduction in tumors [57]. The S. typhimurium strain
VNP20009 is a well-known bacteria in cancer therapy and is a purine axotrophic mutant
with truncated lipopolysaccharides (LPS) due to the deletion of purI and msbB,
respectively [58]. This strain exclusively colonizes tumors but not normal cells.

20

Another exciting application of bacteria in cancer therapy is to exploit them as a
vector for gene therapy. In contrast to virus and non-viral vehicles, bacteria can deliver
genetical elements of various sizes. Therefore, the size of the therapeutic payload is not a
limitation in this delivery system. Bacteria can be used to deliver DNAs, mRNAs, small
interfering RNAs, and proteins into cells [51, 59]. In addition, bacterial vectors can be
systematically administrated through intravenous (iv) or intraperitoneal (ip) methods into
the host. Bacteria have abilities to deliver genes into both solid tumors, e.g. melanoma,
lung, colon, breast, renal, and hepatic, and metastatic cancers [56, 59]. Bacteria can also be
recruited to be involved in gene-directed enzyme prodrug therapy (GDEPT). In this
approach, vectors deliver the construct encoding enzymes such as cytosine deaminase and
purine nucleoside phosphorylase into tumors. These enzymes are able to convert the nontoxic prodrugs into toxic drugs inside tumors. Several bacterial strains, e.g. Listeria and
Bifobacterium, have been reported to deliver conversion enzymes into cancer cells [60].

Bactofection and Alternative Gene Therapy
Generally, bacterial delivery systems consist of two strategies: bactofection and
alternative gene therapy (AGT). The term bactofection was coined for the application of
bacteria as a vehicle to deliver genetic information into phagocytic and nonphagocytic
mammalian cells. In this approach, bacteria enter the target cells carrying a suicide gene,
lyse inside the cells or vacuoles, and a plasmid encoding a therapeutic gene is released
(Figure 1.3) [61].
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Figure 1.3. Bactofection process.

A) Bacterium enters cancer cells. B) Bacterium can replicate inside the cells. C) Plasmid releases
from lysed bacteria into cytosol. D) Plasmid enters nucleus randomly [61].

In bactofection, based on the nature of vectors, bacteria localize in the cytoplasm
(e.g. Listeria and Shigella), in vacuoles (e.g. Salmonella and Yersinia), or in extracellular
space (e.g. Agrobacterium) [62]. The advances in molecular technologies have engendered
the development of various modified bacterial vectors for gene delivery purposes. For
instance, an engineered E. coli strain that carried inv, encoding for invasion, from Y.
pseudotuberculosis and hly from Listeria monocytogenes, expressing Listeriolysin O, was
able to attack the target cells, enter, and deliver a plasmid to cell cytosols [62].

Bactofection, despite advantages like simplicity and specificity, encounters several
drawbacks and limitations. One of the limitations of this approach is the elimination of
vectors by immune systems prior to interacting with cancer cells. Another concern with the
usage of bactofections for therapeutic purposes is that attenuated bacteria might regain their
pathogenicity [62].

Alternative gene therapy (AGT) is another strategy in bacterial therapy. In AGT,
unlike bactofection, bacteria are converted to a factory for synthesizing the therapeutic
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agents inside tumors. AGT is a nucleus-independent approach which reduces the risk of
tumor adaptation compared to other gene therapy strategies [49]. In comparison to classical
gene therapy approaches, AGT can be easily shut down by using antibiotics or by applying
inducible promoters or suicide genes [49]. Several studies suggested that Clostridia,
Bifidobacteria, Salmonella, or Listeria are suitable candidates for AGT purposes. Listeria
has been reported to be able to survive and produce therapeutic proteins directly in the
cytoplasm of target cells [63].

Listeria monocytogenes: A Versatile Vector in Gene Therapy
L. monocytogenes is an intracellular pathogen that can cross three tight barriers in
the human body, i.e., the intestinal, the blood-brain, and the fetoplacental barriers [64].

Listeria is a suitable vector for the delivery of DNA or RNA into target cells. This
ability comes from its life cycle in mammalian cells, which includes a series of consecutive
events: 1) contact with the cells via membrane proteins, 2) entering into the phagocytic
vacuole, 3) lysing the vacuole, 4) replicating inside the cytosol, and 5) spreading from cell
to cell [64].

Listeria is able to enter inside phagocytic (e.g. macrophage or neutrophils) and nonphagocytic cells (hepatocytes and endothelial cells) [64]. However, internalization of this
bacterium occurs as a result of the active interaction between the bacterium and the host
cells. Listeria has two surface proteins, i.e., internalin A (InlA) and internalin B (InlB), that
are involved in listerial entry into different cell lines [63]. E-cadherin, the receptor for InlA,
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and the hepatocyte growth factor (HGF) receptor Met, the receptor for InlB, are located on
the surface of the host cell [65]. Once Listeria enters a cell, it lyses the phagosome by
producing a pore-forming bacterial toxin, listeriolysin-O (LLO), encoded by the hly gene.
Listeria can also secrete phosphatidylcholine phospholipase C (plcB) to escape from a
secondary vacuole [63, 64]. In the cytosol, the bacteria replicate and subsequently express
the ActA protein, which triggers actin polymerization around the bacteria and facilities
several processes such as bacterial movement in the cytosol, the formation of protrusions
at the host cell surface, and bacterial cell-to-cell spread. In addition, ActA is involved in
some other bacterial functions, including entry into the cell, escape from phagosomes,
avoidance of autophagy, and the formation of biofilms [66].

Listeria, a gram positive organism, does not have the lipopolysaccharides (LPS),
bacterial endotoxins that induce inflammation in hosts [67]. However, its pathogenicity
casts a shadow upon its application in gene therapy. Thus, attenuation of its virulence is
required for safety considerations [68]. Today, several attenuated Listeria strains have been
introduced by several research groups. Dietrich et al. developed an attenuated selfdestructing L. monocytogenes to transfer DNA into the host cell macrophage cytosol. This
attenuated bacterium produces a PactA-dependent Listeria-specific phage lysin to initiate
suicide once inside the target cells [69]. Schoen et al. demonstrated the usage of selfdestructing L. monocytogenes carrying the lysin gene from phage A118 (ply 118) to deliver
eGFP mRNA into the cytosol of epithelial cells, macrophages, and human dendritic cells
[62]. Tangency and co-workers produced a highly ampicillin-sensitive host strain L.

monocytogenes that grows in solid tumors and subsequently could be killed after ampicillin
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administration [70]. Yang et al. genetically engineered a replication-deficient strain of L.
monocytogenes (Lmdd) to express and secrete human CD24 protein in cancer stem cells
(CSCs). This attenuated bacterium is deficient for alanine racemase (dal) and D-amino acid
aminotransferase (dat), which are essential for the synthesis of D-alanine. Bacteria lacking
these genes are not able to make the mucopeptide component of the bacterial cell wall,
which is essential for replication, and depend only on the availability of exogenous Dalanine. This bacterium has been shown to be a safe and effective cancer vaccine in
preventing HCC chemoresistance, metastasis, and recurrence [68]. Heisig et al. generated
an internalin A and B (InlAB)-deficient L. monocytogenes strain (Lm-spa+) that expresses
protein A of Staphylococcus aureus (SPA) and anchors SPA in the correct orientation on
the bacterial cell surface. This bacterium can bind to antibodies and be specifically directed
to the target recognized by the antibody [71].

In this project, we intend to increase the safety of the attenuated L. monocytogenes
strain with deleted internalin A and B (Inl AB)-expressing SPA [71] by transferring a
plasmid carrying the self-destructing L. monocytogenes lysin gene from phage A118 (ply
118), which induces listerial suicide once inside the cancer cells.

Objective
Apoptosis, as a regulated cellular mechanism, is essential for various processes,
including normal cell turnover, proper development and functioning of the immune system,
hormone-dependent atrophy, embryonic development, and chemical-induced cell death.
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Inappropriate apoptosis, an important factor in the development of many types of cancer,
occurs due to the disrupted balance of pro-apoptotic and anti-apoptotic proteins, impaired
death receptor signaling, or reduced caspase function. Therefore, any drugs or treatment
strategies that are able to direct the apoptotic signaling pathways towards normality have
the potential to eliminate cancer. The main goal of this dissertation was to introduce a
proof-of-concept application for MazF protein as a potential apoptotic inducer against
cancer. The first aim deals with evaluating the expression of ACA-less mazF mRNA in E.
coli cells. The second aim is to investigate the ability of MazF to inhibit protein synthesis
and eventually trigger death in various cancer cell lines. The third aim explores the
feasibility of using a Listeria delivery system to generate and transfer mazF mRNA into
cancer cells. Data collected in this research would facilitate the development of new cancer
treatment options that target only cancer cells but not healthy cells. Furthermore, such
treatment approaches, based on using bacteria to deliver mRNA to target cells, offer more
advantages, e.g. inexpensiveness, target tissue specificity, and easy and safe delivery, in
comparison to other gene therapy vectors or direct protein administration.
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CHAPTER TWO
2.

Overexpression of ACA-less mazF in Escherichia coli Cells
Introduction

Bacteria are usually exposed to various stressful conditions such as amino-acid
starvation, antibiotics treatment, temperature change, DNA damage, and phage
contamination. Hence, regulation of cell growth and death is crucial for bacterial
populations. Similar to eukaryotes, bacterial cells face programmed cell death (PCD) in
their lifetime. As mentioned above, PCD is defined as any form of death caused by an
intracellular death program [23]. PCD occurs in bacterial cells through various pathways.
Toxin-antitoxin (TA) is one example of an intracellular death program that is present in
almost all bacteria and comprises bicistronic operons containing toxins and antitoxins [36].

MazF is one of the well-known toxins involved in bacterial programmed cell death.
This small endoribonuclease, with a molecular weight of 12 kDa, cleaves mRNA at ACA
sequences in a ribosome-independent manner and restrains bacterial growth during
stressful conditions [36]. MazF is one of the toxins present in the TA Type II system. In
this system, the antitoxin binds to the toxin and precludes toxin functions at normal
conditions. However, under stressful environmental conditions, the toxin is released from
the stable antitoxin-toxin complex, and the antitoxin is degraded by ATP-dependent
proteases [25].
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Engelberg-Kulka et al. studied the influence of the mazEF locus on triggering
programed cell death in bacteria during stressful conditions. According to their results,
once bacteria encounter harsh conditions, such as extreme amino acid starvation, inhibition
of transcription and/or translation by antibiotics, lethal action of toxic phage products and
DNA damage caused by thymine starvation, UV irradiation, oxidative stress, and DNA
damaging agents, the expression of both MazF and MazE is halted. In this situation, MazE,
as the corresponding antitoxin to MazF, is degraded by the ATP-dependent serine protease
clpPA, while MazF is released to digest mRNAs in cells. Hazan et al. found that E. coli
ΔmazEF are more resistant to high temperatures (50ºC) and DNA damage by nalidixic acid
(at concentrations of 2 mg/ml and lower) and mitomycin C (at concentrations of 1.5 µg/ml
and lower) [73]. During stress, the MazEF operon is downregulated, and the concentration
of MazE, due to its unstable nature, drastically drops, while MazF proteins are unleashed
and function in cells [29]. The MazEF system also serves as a defense mechanism against
phage spread. It has been shown that E. coli ΔmazF is susceptible to infection and being
completely killed by P1phage, while in the wild-type (WT), infected cells are killed by the
MazEF system, as opposed to the phage. The WT culture survives and grows normally, but
phage spread is restricted. In other words, MazEF saves the whole population by
eliminating the individual infected cells [29].

Recently, two genetically distinct programmed cell death pathways, apoptotic-like
death (ALD) and the MazEF pathway, have been described for E. coli populations. ALD
shares some similarity in morphological changes (such as membrane depolarization and
DNA fragmentation) with eukaryotic apoptosis. ALD is the recA-dependent cell death
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pathway and is triggered exclusively by DNA damage [74]. Erental and colleagues have
shown that mazEF is a recA-independent pathway, which prevents the activation of the
ALD pathway, either by cleaving mRNAs of recA or by inhibiting recA transcription.
According to their model, mazEF rescues the small bacterial population that is resistant to
various stressful conditions. Whereas, ALD allows the survival of those individual cells
that either escape from or repair DNA damage [74].

MazF is known as an RNA restriction enzyme [37]. It has been reported that
RNA/DNA or RNA/RNA duplexes or single stranded DNA are resistant to MazF action.
In addition, several mRNAs have been found to be resistant to MazF. One example of these
mRNAs unsusceptible to MazF is lpp mRNA, which possesses four ACA triplets in its
sequence. Zhang et al. showed that the secondary structure of RNA caused three ACA
sequences of this mRNA to be inaccessible to MazF proteins, and only one of the ACA
sets is removed from mRNA, which does not affect the expression of lipoprotein, one of
the abundant proteins in E. coli cells [37].

The presence of ACA codons in the mazF sequence enables this ribonuclease to
degrade its own mazF mRNAs, leading to inhibition of protein synthesis in cells [37]. To
avoid the elimination of mazF mRNA by itself, the application of an ACA-less mazF gene
was used in this research. To validate the expression and function of an ACA-less mazF in
E. coli cells, this construct was placed under the control of a stringent promoter, and the
bacterial viability was monitored.
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Experimental Section
General Molecular Techniques
Gel electrophoresis: DNA, due to its phosphate residues in the backbone, is
negatively charged. These electrical charges direct DNA toward the positive pole in a
constant electrical field, which makes it possible to separate DNA in a size manner on
agarose gel.

The concentration of the agarose gels was prepared based on the size of DNA
plasmids or fragments in 1X TAE buffer. The DNA samples were mixed with 1X loading
dye and loaded in gel wells. Gels were post-stained with 1X Gel RED, and DNA bands
were visualized under UV-light.

Plasmid extraction: Plasmid extraction was conducted using commercial Qiagen
Kits (Qiagen, USA). Plasmids were extracted from 100 ml of bacterial culture
supplemented with appropriate antibiotics. All procedures were carried out according to
the manufacture’s protocol.

Gel purification: Gel purification was performed by using QIAquick Gel
Extraction Kit (Qiagen, USA). First, samples were loaded into wells of a low-melting-point
(LMP) agarose gel. Since UV has a mutagenic effect on DNA, the gel was stained with
Gelgreen stain (Biotium, USA) and visualized under a blue light transilluminator. Samples
were excised from the gel and mixed with Buffer QG (Qiagen, USA). To melt the gel, the
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mixture was incubated at 50ºC and subsequently subjected to further purification according
to Qiagen’s protocol.

DNA restriction: In this project, restriction enzymes were used for assembly and
also validation purposes. The restriction enzymes were type II endonucleases, which were
selected based on the presence of their restriction sites on DNA. For digestion reactions, 25µg of DNA was used in a 50µl volume with 5-10 units of restriction enzymes. The
digestion buffers were selected according to the manufacture’s recommendations. The
reactions were incubated overnight at 37ºC. The heat-sensitive enzymes were deactivated
at the recommended temperatures for 10-20 minutes.

Ligation: Ligation is defined as linking the sugar-phosphate backbones of two or
more double-stranded DNAs by ligase enzymes. The purity and the concentration of DNA
and the presence of ATP in ligase buffers are the most important elements in a ligase
reaction. The ligation reactions were prepared in vector:insert ratios between 1:1 to 1:3,
although the ratio was optimized for each reaction separately. T4 DNA ligase (New
England biolabs, USA) was used for the ligation purpose, and reactions were incubated at
16ºC or 4ºC overnight.

Construction of ACA-less mazF in E. coli Cells
The ACA-less mazF is a toxin-encoding gene that can kill transformed bacteria at
the early stage of growth. Thus, the presence of a stringent promoter is required to express
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mazF gene at the exact expected time. mazF gene was placed under the control of a pBAD
promoter, which is induced by arabinose.

The synthesized ACA-less mazF is 336 bp and does not carry the ribosome binding
site. To amplify the ACA-less mazF fragment, a set of primers were designed: Forward
(X-mz-F) and Reverse (H-mz-R) primers (Table 2.1). The forward and reverse primers
contain XhoI and HindIII restriction sites, respectively. Because the mazF fragment is
short, the digestion process did not occur properly. Hence, the amplicons were first
appended with poly-A at both end sites and then directly ligated to the linearized pGEM®T Easy vector. This vector contains the α-peptide coding region of the enzyme βgalactosidase, enabling blue/white screening of clones containing the insert. Plasmid
pGEM®-T containing mazF was electroporated into E. coli DH10B. Following the
purification of the transformed bacteria, the vector was isolated using QIAprep Spin
Miniprep Kit and sequenced. Plasmid pGEM®-T harbouring the right insert was digested
using XhoI and HindIII restriction enzymes, and ACA-less mazF was extracted using
QIAquick Gel Extraction Kit.

Table 2.1. Designed primers for construction of pGEM-Z
Primers

Sequences

Applications

X-mz-F

ACTATACTCGAGATGGTAAGCCGATACG

Amplification of mazF fragment for pGEM-mazF

H-mz-R

GTTAGCCTCCCCCAAGCTTTCACCC

construction

The pBAD-His vector was purchased from Invitrogen. The optimized ribosome
binding site, araBAD promoter (PBAD), N-terminal polyhistidine tag, and araC gene are
some of the features of the pBAD-His vector (Figure 2.1). The vector was digested with
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XhoI and HindIII restriction enzymes and purified using QIAquick Gel Extraction Kit. The
XhoI-HindIII digested ACA-less mazF fragment was inserted into the digested pBAD-His.
E. coli DH10B was the host of the construct. The construct was stored at -20ºC.

Figure 2.1. pBAD vector map
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Overexpression of MazF Proteins in E. coli Cells
In order to express the low basal level of MazF without induction, the above
construct was electroporated into E. coli LMG 194, which was purchased from Invitrogen.
The genotype of this strain is F- ΔlacX74 galE thi rpsL ΔphoA (Pvu II) Δara714 leu::Tn10.

The transformed bacteria were grown overnight on M9 minimal medium supplied
with 0.1% glucose and 10% casamino acid. The bacterial culture was diluted in fresh M9
medium, and the OD was measured at 600 nm every 30 minutes. As the bacteria reached
their mid-logarithmic phase (OD600 = 0.5), the culture was split into two flasks: one flask
with 0.2% arabinose and the other one as a control. Both flasks were incubated at 37ºC
without shaking, and after 20 minutes, 1 ml from each sample was withdrawn and used for
further dilution in PBS. One hundred microliters of diluted samples was spread on M9ampicilin plates and recorded as time 0. Then, samples were collected at various time
points: 20 min, 40 min, 1 hour, 2 hours, 4 hours, and 6 hours in the same manner.

Results
MazF is a bacterial toxin that can cleave 90% of mRNA at ACA sequences and
induce death in E. coli cells [73]. To monitor the effect of MazF proteins on bacterial cells,
ACA-less mazF was inserted downstream of an inducer promoter, pBAD (Figure 2.2). This
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promoter is a tightly regulated promoter of the arabinose operon and induced by the
presence of arabinose as the carbon source in the bacterial medium.

Figure 2.2. pBAD-mazF map

To analyze the effect of MazF on bacterial viability, the pBAD construct was
electroporated into E. coli LMG 194. The transformed bacterial cells were grown in M9
minimal medium to mid-logarithmic phase. The expression of MazF protein was induced
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by the addition of arabinose in the culture medium. The bacterial samples were then
cultured on M9 medium, and the CFU/ml was calculated for each time point.

The result showed that overexpression of mazF led to drastically decreased colony
sizes and also caused a 6-log reduction in bacterial viability during a period of 6 hours
(Figure 2.3 and Figure 2.4). Our result was consistent with other studies, which used
unmodified mazF sequences in bacterial cells [75].
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40 minutes

20 minutes

Figure 2.3. The effect of overproduced MazF protein on E. coli LMG 194

The top plates: the mazF gene was induced by addition of arabinose at 20 minutes and 40 minutes.
As shown, the number and size of bacterial colonies reduced severely compared to controls. The
below plates: MazF protein was not induced in bacterial cells (controls for the same time point).
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Figure 2.4. The percentage of bacterial survivors after mazF induction. The blue line is related to the
percentage of cells in which mazF was not induced (control).
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Discussion
MazF protein is one of the bacterial toxins that plays an important role in the
regulation of bacterial populations during stationary phases. This protein can block protein
synthesis and eventually arrest bacterial growth during harsh conditions. MazF proteins are
described as a bacterial ribonuclease that digests mRNAs at ACA sequences. This protein
is also able to cleave its own mRNA due to the presence of ACA codons in its sequence.
This might be one of the reasons that the expression of MazF and MazE is inhibited during
harsh conditions [76]. In this research, we investigated the effect of overexpressed ACAless mazF on bacterial cells.

To examine the lethal ability of the overexpressed MazF protein, ACA-less mazF
was inserted under the control of the PBAD promoter, and the construct was transferred into
E. coli cells. The transformed bacteria were used to validate the expression of MazF
protein. Our results showed that significant reduction occurred in bacterial viability shortly
after the induction of the PBAD promoters. In addition, the surviving bacteria generated
smaller colonies compared to the control strain. Also, our result recorded approximately 6log reductions in bacterial viability 6 hours post induction. Therefore, these data confirmed
that MazF was overproduced in bacterial cells, and MazE proteins were unable to
neutralize the function of MazF in bacterial cells. Our result was in agreement with findings
reported by Amitai et al. [76], indicating that overexpression of MazF proteins can mediate
death in bacterial cells.
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CHAPTER THREE
3.

MazF: A Potential Apoptotic Inducer in Various Cancer Lines
Introduction
Cancer and Ribonucleases
Despite recent advances in treatment and diagnostic measures, cancer continues to

plague the medical community. The second leading cause of mortality and morbidity
worldwide, cancer is a group of diseases sharing limited common characteristics that arise
from various mutations [77]. This heterogeneity has been a major challenge for cancer
therapy, since these mutations often compromise the success of treatment. Traditionally,
the battle against cancer has been led by surgery, chemotherapy, and radiotherapy.
However, these treatment methods suffer from various limitations (e.g., the lack of
specificity in the traditional strategies) and side effects, including both temporary (e.g.,
diarrhea, nausea, loss of hair, reduced resistance to infection) and long-term effects (e.g.,
decreased heart, lung, and kidney health). In an attempt to avoid these drawbacks, recent
treatment efforts have focused on introducing certain drugs or small toxins with mild
toxicities and tolerable immunogenicity [78].

Ribonucleases have been a promising route in cancer therapy at gene expression
levels [79]. Ribonucleases, or RNases, are defined as small basic proteins, 10-15 kDa, that
degrade RNA molecules. Based on their activity, sequence, and structure, these proteins
are classified into two main groups: endoribonucleases and exoribonucleases [79]. The
actions of RNases have diverse effects on cellular events. RNases have the ability to
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function as angiogenic, neurotoxic, antitumor, or immunosuppressive agents [80].
Paradigm onconase from the northern leopard frog (Rana pipiens) is a well-known example
of an RNase that could serve as a potential treatment against a variety of malignancies [80].
In addition, several endeavors have been made to design RNases with high toxicity and
specificity against cancer tumors [81, 82].

Ribonucleases naturally occur in prokaryotic and eukaryotic cells, and are not
limited to fungi, plants, and animals. RNases have been harvested from several mushroom
species for therapeutic uses, including Cordyceps sinensis, C. militaris, Coriolus
versicolor, Ganoderma lucidum, Grifola frondosa, and Hericium erinaceus. The
mushroom Calvatia caelata produces a ubiquitin-like 8-kDa peptide that has been shown
to suppress breast cancer proliferation. This mushroom also contains the RNase calcaelin,
which has antimitogenic activity in mouse splenocytes and a lethal effect on breast cancer
cells [82].

RNases also are present in many plant organelles, including chloroplasts, vacuoles,
nuclei, and mitochondria [83]. These RNases are involved in a series of biological activities
such as self-incompatibility, programmed cell death, response to phosphate starvation,
plant defense, and plant development. The Japanese pear (Pyrus pyrifolia), Arabidopsis,
tomato plants, and wild almonds (Prunus webbii) are all known to produce RNases. The
ginseng plant is known to generate various anti-cancer and anti-HIV-RT RNases. It has
also been reported that RNases extracted from wheat leaf, mung bean, black pine pollen,
tomato, and hop will prevent the proliferation of cancer cells [79, 84, 85].
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Animal cells contain various RNases such as onconase, ranpirnase (commercial
name), or P30 (initial name) that have been tested in phase III trials against mesothelioma
[86]. Onconase is extracted from the embryos and unfertilized oocytes of northern leopard
frogs and belongs to the RNase A superfamily [86, 87]. These proteins, due to their
stability, low catalytic activity, and low immunogenicity have been nominated as a
potential treatment against cancer. Other examples of animal-derived RNases that show
therapeutic activity against cancer and HIV include bovine pancreatic RNase A (BPRNase), bovine seminal RNase (BS-RNase), and human pancreatic RNase (HP-RNase)
[87].

Bacteria also generate diverse groups of RNase proteins with different cytotoxic
abilities. Extracted from Bacillus intermedius and a member of the bacterial T1 RNase
family, Binase specifically inhibits proliferation of and induces apoptosis in human
myelogenic erythroleukemia K562 cells, human lung carcinoma A549 cells, and human
peripheral blood mononuclear cells [88]. RNase Sa3, another member of the bacterial T1
family of RNases, is isolated from Streptomyces aureofaciens (strain CCM 3239). This
protein selectively targets human erythroleukemia K562 cells in culture at a low
concentration [89].

mRNA-Based Therapies
Nucleic acid-encoded drugs have opened a window to battling various lifethreatening diseases. These drugs traditionally have been employed to modify gene
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expression or edit genes within the genome [90]. Wolff et al., as the pioneer of developing
these new treatments, showed that the direct injection of DNA and RNA into murine
skeletal muscle initiates the encoded protein expression in the same muscle [91]. At the
time, pDNA and viral DNA-based approaches attracted the highest attention against
various diseases, while mRNA-based drugs, owing to the labile structure of mRNA,
remained unpursued for a long time. Although mRNA was discovered in 1961, its
structure, stability, function, and metabolic relevance were, until recently, the main focuses
of mRNA studies [92]. Since the 1990s, various strategies have been described for the
application and improvement of in vitro transcribed mRNA (IVT mRNA) limitations, e.g.
their short half-life, and immunogenicity against cancer and infectious diseases [92-94].

Unlike other nucleic acid-based therapies, IVT-mRNA-based therapy offers
exceptional advantages in the medical field. IVT mRNA does not seek access to the nucleus
but is instead functional in the cytoplasm. Thus, mRNA can be translated in both dividing
and non-dividing cells. In contrast to plasmid DNA and viral vectors, IVT mRNA bears no
risk of genomic integration and insertional mutagenesis. Unlike DNA, IVT mRNA does
not need to possess a strong promoter or a terminator to be expressed inside the cells [90,
92]. Moreover, mRNA can be applied to encode nucleases, e.g. zinc finger motifs (ZFN),
TALEN–transcription activator-like effector nucleases (TALEN), and CRISPR Cas9, for
gene editing purposes [90]. Another advantage of mRNA over pDNA is the lack of
immunogenic CpG motifs, which enhances the transfection efficiency and safety profile of
mRNA-based treatments. Both bacterial and certain viral DNA carry unmethylated CpG
(cytosine–phosphate–guanine) motifs that make them vulnerable to the immune system.
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The bacterial DNA containing CpG motifs activates B cells, monocytes, dendritic cells,
macrophages, and the lytic activity of natural killer cells that subsequently leads to failed
gene deliveries in vivo [95].

In general, IVT mRNA has been utilized in two therapeutic applications. One
application delivers mRNA into the patient’s cells ex vivo for genome engineering, genetic
reprogramming, T cell- and dendritic cell (DC)-based immunotherapies against cancer and
infectious diseases, and certain protein-replacement approaches [92]. The second
application transfers mRNA to cells in a variety of ways for vaccination, oncology,
infectious disease, tolerization regimens to battle allergies, and for other proteinreplacement therapies [92].
To function as a pharmacologically active drug, IVT mRNA exploits cells’
translational machinery in order to be expressed inside cells. IVT mRNA shares similar
structures with naturally mature mRNAs and undergoes translation in the cytoplasm [92].
IVT mRNA is a single-stranded molecule containing a 5´ cap (m7GpppN or m7Gp3N (N
–any nucleotide)), a 5′- untranslated region (5′-UTR) and a protein-encoding open reading
frame (ORF), a 3′-untranslated region (3′-UTR), and a 100-250 adenosine-containing
region (3′- poly(A)-tail) [90, 92].

The mRNA usually possesses a long string of nucleotides that causes chemicallyautomated mRNA synthesis to be impracticable, but in this case, mRNA synthesis is solely
linked to in vitro enzymatic synthesis or cell-free systems. In cell-free systems, a linearized
plasmid or PCR product serves as a template to encode all structural elements of mRNA,
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with the exception of the 5´ cap. The template DNA contains either the T7 or SP6 promoter,
to be paired with the corresponding RNA polymerase in vitro transcriptional reactions. The
polymerases utilize nucleotides to generate and elongate mRNAs. Consequently, the cap
is incorporated into the mRNA through an enzymatic reaction. The template DNA is then
eliminated by DNases, and the synthesized mRNA is purified [92].

In order to be translated, IVT mRNA must be transported from extracellular space
to its final destination, the cytoplasm. Both the activity of ubiquitous RNases in
extracellular space and the cell membrane determine the fate and cytoplasmic
bioavailability of IVT mRNA. Hence, transfection approaches should be designed to
protect the mRNAs from destruction by RNases and enhance their cellular uptakes [92].

When placed in the cytoplasm, stability and translation of IVT and native mRNAs
are controlled by identical complex cellular mechanisms. The IVT mRNA is then translated
to a protein product which functions as a bioactive compound [92].

The success of mRNA-based therapeutics depends on many factors such as the
quantity of in vitro transcription products, intracellular stability of IVT mRNA, and its
translational efficiency. In general, mRNA-based therapies, in spite of their advantages,
have faced skepticism rooted in the instability and short half-life of mRNAs. mRNA has a
hydroxyl group on the second carbon of its sugar moiety that inhibits the formation of
stable double-ß-helix structures and facilitates mRNA hydrolytic destruction [95].
Recently, several modifications in various mRNA structural elements such as 5´ caps, 5´
and 3´- UTRs, coding regions, and Poly-A tails have been established to improve IVT
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mRNA stability, translocation, and translation in cells. These modifications eventually
enhance the synthesis of the encoded protein in transformed cells [90, 92].

The 5´ cap is a key structural element in mRNA stability, transport, and translation.
Eukaryotic mRNA possesses a 7-methylguanosine (m7G) cap linked to the first transcribed
mRNA nucleotide via a 5ʹ-5ʹ-triphosphate bridge (ppp) (m7GpppN structure) [90, 95]. In
the nucleus, a cap-binding protein (CBP) heterodimer, CBP80-CBP20, interacts with caps
and ushers mRNAs to the cytoplasm. This complex is also responsible for eliminating
prematurely translated mRNAs through nonsense-mediated mRNA decay (NMD). The cap
structure prevents degradation of mRNA against Xrn1 in the cytoplasm and Xrn2 in the
nucleus [96]. Facilitation of mRNA translation is another important role of the 5’ cap. Caps
bind to the CBP complex and the eukaryotic initiation factor 4F (eIF4F) before directing
the 40S ribosomal subunit to the mRNAs in order to enhance the translational process
[97].

During in vitro transcription, the capping process is accomplished via two different
approaches. In one procedure, the synthesized mRNAs are capped with the recombinant
vaccinia virus-derived capping enzymes, while the second approach is to supplement the
IVT reactions with cap analogs in a single step. However, due to the competition between
GTP and the cap analog, both approaches unfortunately result in the appearance of
uncapped and translationally inactive mRNAs [90, 92, 95]. Moreover, m7GppG can be
linked in two orientations, Gpppm7GpN and m7GpppGpN, which causes half of the IVT
products to remain unrecognizable to ribosomes inside of cells [90, 92, 95]. Recently,
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various cap-analogs have been commercially introduced to prevent reverse bindings and
enhance the translational efficiency of IVT mRNAs. Phosphorothioate-containing ARCA
cap analogs and asymmetric cap-analogs carrying methylated guanosine residues at their
N7 atoms [90] or anti-reverse cap analogs (ARCAs, m27,3ʹ−OGpppG) have been designed
to boost the translation and stability of IVT mRNAs [90, 92]. Tavernier et al. compared
the impact of a regular (mCAP) with an anti-reverse analog (mARCA) on the expression
of luciferase in Hela cells. Their results showed that an ARCA in mRNA structures
prolongs expression of the luciferase to 5-7 days post transfection [95]. Kuhn et al. reported
that the IVT mRNAs capped by a phosphorothioate-modified cap result in a higher stability
profile when compared to the transcript capped with a mCAP. However, the success of
IVT mRNA bioavailability and translational efficiency depends on multiple parameters
including cell type, cell differentiation state, and delivery system [98].

In eukaryotic cells, protein translation is a strictly regulated process that begins with
the recognition of a 5´modified nucleotide cap of mRNA via several initiation factor (eIF)
proteins and is followed by ribosomes scanning mRNA nucleotides to identify the start
codon. Hence, the 5´ cap plays a crucial role in the canonical pathway of translation
initiation. However, several eukaryotic and viral mRNAs have been found to be cap-less
and bypass the canonical pathways. These mRNAs contain specific RNA sequences in
untranslated regions (UTR) called internal ribosome-entry sites (IRESs) that facilitate the
interaction of the 40S ribosome to the adjoining sequences of the initiation codon [99].
Poliovirus (PV) and encephalomyocarditis virus (EMCV) are well-studied examples of
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cap-independent and end-independent RNAs where their IRES sequences protect and boost
the translation of the viral mRNAs in mammalian cytosols [100].

The viral IRESs are categorized in four groups based on the following criteria:
involvement of initiation factors, secondary structure of the IRESs, vicinity of the start
codon to the IRES, and ability of the IRES to function in rabbit reticulocyte extract with or
without supplementation [99, 100]. Group one contains IRES RNAs that directly bind to
ribosomes. This group is eIF- and initiator methionyl-tRNAi-independent and includes
Cricket paralysis virus (CrPV) and Plautia stali intestine virus (PSIV) [101].

In the second group, IRES RNAs interact with the 40S subunit and engage a subset
of canonical eIFs (eIF3, eIF2) and Met-tRNAi. HCV, classical swine fever virus (CSFV, a
pestivirus) and porcine teschovirus (PTV-1, a picornavirus) are members of this second
group [101, 102].

Translation in group three initiates through the association of IRES RNAs with
canonical eIFs, Met-tRNAi, and additional proteins called IRES trans-activating factors
(ITAFs). These mRNAs can be translated in rabbit reticulocyte lysates and the AUG codon
placed at the 3´ ends of IRES. Group 3 includes EMCV, FMDV, and Theiler’s Murine
Encephalomyelitis virus (TMEV) [103-105].

In contrast to group three, group four IRES RNAs are only translated in
supplemented rabbit reticulocyte lysates with other cell type extracts with the start codon
located relatively downstream of the IRES. Despite the involvement of viral mRNA, the
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diverse sequences and the unpredictable secondary structures of cellular mRNAs are the
largest obstacles to the classification of mammalian IRESs [105-107].

The discovery of IRES in 1988 shed light on the enigmatic translation of the RNAs
of human pathogens but also offered a versatile tool for gene therapy. The development of
vectors with the ability to transfer and introduce multiple genes has been a notable
challenge for gene therapy. Complex disorders such as cancer and certain infectious
diseases, e.g. HIV-1 (human immunodeficiency virus), require use of multiple genes and
may also attack various targets within the cells. The availability of a selectable marker
for the purposes of gene detection is yet another desired feature of gene therapy vectors
[108]. Thus, the introduction of co-expressed multiple gene systems is highly valued in
designing gene therapy vectors. IRES provides the means to design polycistronic
constructs carrying two or more separated genes under the control of a single promoter.
Morgan et al. (1992) designed an IRES retroviral vector co-expressing a drug-selectable
marker and a reporter gene [109]. Felipe and Izquierdo (2000) developed tricistronic and
tetracistronic vectors for multigene therapy. These retroviral vectors carry genes
downstream of the internal ribosome entry sites (IRESs) of the encephalomyocarditis virus
(ECMV) [110].

IRES has been utilized in various therapeutic strategies against cancer and complex
diseases. In one strategy, IRES is incorporated upstream of a selectable marker or a reporter
gene which detects stable expression of the therapeutic gene in cells. IRES can also be used
to co-express various subunits of multimeric proteins [111]. Another IRES strategy is to
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co-express a suicide gene and an immunomodulating gene in cancer cells [112, 113]. In
addition, IRES can be implemented to deliver drug resistance genes into hematopoietic
progenitor cells. This approach can reduce the chance of myelosuppression caused by highdose chemotherapy [114].
Eukaryotic mRNAs possess a poly-A tail at their 3´ ends that enhances the mRNAs’
stability and translational efficiency [92]. The presence of a poly-A tail is also crucial for
the transport of mature mRNAs to the cytoplasm [115]. Polyadenylation of IVT mRNA is
conducted either through the presence of poly-T in the template vector or by an enzymatic
two-step reaction in which recombinant poly-A polymerase incorporates modified
nucleotides to the poly-A tail. A key limitation of enzymatic polyadenylation is the
resulting mixture of RNAs with varying lengths of poly-A tails. However, the IVT mRNAs
rooted in a co-transcriptional fashion have a defined poly-A tail length. The optimal length
of the poly-A tail to decrease the immunogenicity of mRNA has been reported to be
between 120 and 150 nucleotides [90, 92, 115].

The translation and stability of IVT mRNAs can also be enhanced by incorporating
5ʹ- and 3ʹ-UTRs carrying regulatory sequence elements [92]. UTRs are also involved in the
transport of mRNAs into the cytosol as well as subcellular localization. UTRs govern these
functions through the interaction of nucleotide patterns or motifs located in 5' UTRs and 3'
UTRs with specific RNA-binding proteins, an association of sequence elements placed in
the UTRs with specific complementary non-coding RNAs, or the interaction between
repetitive elements and binding proteins [116]. The sequence of UTRs is believed to
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contribute to the stability of mRNA. The 3′-UTR carrying adenosine/uridine-rich
sequences produces unstable mRNAs in cells, while the replacement of the AU-rich
regions with the sequence from a durable UTR extends the half-life of the mRNAs [90].

The translational efficiency can also be influenced by codon composition and any
adjacent nucleotides which might stimulate overexpression or downregulation of the gene
of interest [92, 117]. Cannarozzi et al. revealed that the usage of the same codon for a
particular amino acid and same tRNAs accelerate the translation process [117]. Hence, the
optimization of the codon content may be another factor to augment protein expression.
Van Gulck et al. demonstrated that the codon-optimized IVT mRNAs could be potentially
applied as a vaccine against HIV [118].

However, the usage of optimized codons can give rise to some concerns for
improper folding of proteins in high speed translations and vaccine failure in induction of
modified ORFs [90]. Optimized codons may also increase the chance of cryptic T cell
epitope formations [90].

Another approach to improve stability and immunogenicity is the implementation
of modified nucleotides in IVT mRNAs. These nucleotides escape the recognition of
exogenous mRNAs by Toll-like receptors (TLRs) and also reduce the toxicity of mRNAs
[90]. In human cells, TLR3, TLR7, and TLR8 are responsible for tracking foreign mRNA
in cells. TLR7 and TLR3 activate with uridine-rich single-stranded RNAs and doublestranded RNAs, respectively, and both receptors interact with hairpin secondary structures,
double-stranded regions

of mRNA

[90]. Modified
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nucleotides

such as

2′-

Omethylnucleosides,

5-methylcytidine

(m5C),

N6-methyladenosine

(m6A),

5-

methyluridine (m5U), pseudouridine, and 2-thiouridine assist mRNAs in evading detection
by TLR3, TLR7, TLR8, and RIG-I receptors. It has been reported that the incorporation of
pseudouridine, a natural nucleotide, in IVT mRNAs boosts the translational efficiency,
stabilization of primary and secondary structures of mRNAs, and lessens its
immunogenicity. The incorporations of pseudouridine and 2-thiouridine in IVT mRNA
structures conceal the mRNA to be recognized by RIG-I and protein kinases (PKR).
However, the usage of specific modified nucleotides, e.g. N 6 -methyladenine, stimulates
the degradation of IVT mRNA by YTH family proteins [90, 92].

RNA therapy has been hailed as an attractive therapeutic approach to battle a broad
range of diseases and disorders. The application of IVT mRNAs has been explored in
immunotherapeutics,

protein-replacement

therapies,

and

regenerative

medicine

applications. In cancer, IVT mRNAs have been subjected to several preclinical and clinical
trials that have led to the introduction of effective vaccines against cancer [92]. One of the
exciting applications of mRNA is the improvement of cancer immunizations. This idea was
influenced by the ability of exogenous mRNA to stimulate the release of proinflammatory
cytokines such as TNF-α, IL-1β, IL-12, IL-6, and IL-8; the secretion of type I interferons
(IFN-α and IFN-β); chemokines GRO, MCP-1, RANTES, and MDC; and the maturation
of antigen-presenting cells, which trigger both innate and adaptive immune cells [90].
Boczkowski et al. showed that immunization of mice carrying tumors with DCs pulsed
with RNA encoding specific antigens stimulates T cell immune responses and stops the
growth of small tumors [119]. The result of this research and other investigations have
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opened doors to the development of ex vivo IVT mRNA vaccines for cancer patients. These
vaccines have been used against melanoma, prostate cancer, hematological malignancies,
ovarian cancer, lymphoma, leukemia, and mesothelioma [92]. Since 1993, the design of
IVT mRNA against infectious diseases has attracted high amounts of attention in the
medical fields. Recently, three types of IVT mRNA–based vaccines have been presented
in pharmaceutical markets. DCs carrying IVT mRNA encoding HIV proteins have been
shown to immunize HIV patients against the virus [120]. The safety and ability of this
vaccine to stimulate antigen-specific CD8+ and CD4+ T cell responses have been
demonstrated in Phase I/II clinical trials [121]. The other types of IVT vaccines are the
injection of adjuvant and naked IVT mRNA encoded to express influenza haemagglutinin
antigen alone and the injection of influenza IVT mRNA with neuraminidase-encoding IVT
mRNA [92]. Other IVT mRNA vaccines have been used for immunization against
flavivirus, RSV, influenza and parainfluenza virus infection [122, 123]. The strong
capacity of mRNAs to stimulate the immune system, together with the short half-life of
mRNAs, has suggested a new application for IVT mRNA: allergy vaccines [92]. This
vaccine, due to the unstable nature of mRNAs, has a higher safety profile and lower risk
of anaphylactic side effects than DNA-based allergy vaccines [90, 92]. It has been shown
that IVT mRNA encoding for Vascular Endothelial Growth Factor (VEGF) can be utilized
for vessel regeneration in cardiovascular diseases [124]. Interestingly, The IVT mRNAbased methods have been promising approaches in various fields, including
reprogramming fibroblast differentiation [125], induction of pluripotent stem cells [125],
and genome editing (ZFN, TALEN, CRISPR-Cas9) [90, 92].
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In this research, we used the IVT mRNA technique to synthesize mazF mRNAs
and deliver the developed mRNAs into cancer cells. The expression of the IVT mazF
mRNA and the effects of MazF proteins on cancer cells are discussed in detail.

Experimental Section
General Molecular Techniques:
Bacterial culture: For all genetic modifications, Escherichia coli DH10B was used
as the host. This strain was cultured in Lysogeny broth (LB) or LB agar media at 37°C.
The overnight cultures originated from a single colony. To maintain plasmids, appropriate
antibiotics were added to growth cultures.

Electrocompetent cells: Since E. coli cells are not intrinsically competent to
acquire plasmids, it is necessary to prepare competent cells prior to transformation.
Transformation of E. coli cells can be performed via several physical approaches. Overall,
it seems that electroporation is the most efficient transformation method. Hence, competent
cells were prepared to be suitable for this method. The electrocompetent cells were
prepared based on Samsbrug et al.’s protocol. A single colony of E. coli was used to
inoculate 50 ml of LB medium, and cells were incubated overnight at 37°C with vigorous
aeration (250 rpm in a rotary shaker). The overnight culture was obtained to inoculate
prewarmed LB medium in separate 2-liter flasks. The flasks were incubated at 37°C until
OD600 reached 0.4. The flasks were then placed on ice for 15-30 minutes. The cells were
harvested by centrifugation at 1000 ×g (2500 rpm) for 20 minutes at 4°C. The cells were
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resuspended in ice-cold deionized water, followed by another centrifugation for 20 minutes
at 4°C. The cells were then washed three times with ice-cold 10% glycerol. Eventually,
the cells were resuspended in GYT (0.125% (w/v) yeast extract and 10% (v/v) glycerol).
The competent cells were aliquoted into centrifuge tubes which were then exposed to liquid
nitrogen. The frozen tubes were maintained at -80°C.

Plasmid Construction
pcDNA3.3-mazF vector was generated by replacing GFP with ACA-less mazF in
pcDNA3.3_eGFP (Addgne, cat# 26822, USA), which contains the T7 promoter. ACA-less
mazF was amplified from pBApo-mazF (kindly provided by Takara) by using the forward
(mz-3.3F) and reverse (mz-3.3R): 5’- primers-3’ primers. The linearized pcDNA3.3_eGFP
was generated with forward (3.3VF) and reverse (3.3VR) primers. The pcDNA 3.1-IRESmazF vector was developed by substituting GFP with ACA-less mazF in pcDNA3.1(+)
IRES (purchased from Addgene, cat#51406, USA) by overlapping PCR. To this end, the
ACA-less mazF fragment was generated by applying the forward (3.1mzF) and reverse
(3.1mzR), and pcDNA3.1(+) IRES was linearized by using the forward (3.1VF) and
reverse (3.1VR) primers.

The ACA-less mazF fragment and the linear corresponding plasmids were ligated
by using the NEBbuilder HIFI DNA assembly kit (New England Biolabs Inc., USA),
according to the manufacturer’s instructions. pT7-IRES-EMCV was purchased from
Oxford genetics Lab, UK. The pT7-IRES-mazF vector was designed by placing the ACA-
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less mazF fragment between NcoI and XbaI digestion sites in pT7-IRES-EMCV.
Eventually, the ligated products were electro-transfected into Escherichia coli Dh10B.

In Vitro mRNA Synthesis
T7-mazF

and

T7-GFP

were

amplified

from

pcDNA3.3-mazF

and

pcDNA3.3_eGFP, respectively, with the forward (G-in-F) and reverse (G-in-R) primers
[126]. pcDNA3.1(+) IRES and pcDNA 3.1-IRES-mazF were used as the DNA templates
for T7-IRES-GFP and T7-IRES-mazF amplicons by the forward (IZ-in-F) and the reverse
(IZ-in-R). To eliminate the plasmid templates, the PCR reaction was degraded by DNPI
(New England Biolabs Inc., USA). The PCR products were then purified by using
QIAquick PCR purification kit (Qiagen, USA), and the purified fragments were used to
generate mRNAs via MEGAscript T7 kit (Life Technologies, USA). In vitro transcription
(IVT) reactions contained ATP, CTP, and GTP from MEGAscript T7 kit, Pseudo-UTP ()
and

Anti-Reverse

Cap

Analog,

3´-O-Me-m7G(5')

ppp

(5')G

(from

TriLink

BioTechnologies, USA), and mazF PCR products and T7 Polymerase (from MEGAscript
T7 kit). The IVT reactions were incubated at 37ºC overnight. To destroy the DNA template
and exclude the 5’ triphosphates, the IVT reactions were cured with Turbo DNase (from
MEGAscript T7 kit) and Antarctic phosphatase (New England Biolabs Inc., USA),
respectively, which was followed by purification of IVT with RNeasy Mini Kit (Qiagen,
USA). The quality of RNA samples was analyzed by formaldehyde agarose gel
electrophoreses. The synthesized mRNAs were stored at -80ºC.
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Table 3.1. List of primers used in this research for construction of pcDNA3.3-mazF and pcDNA3.1 (+) IRES-mazF and preparation of DNA templates
for in vitro transcription purposes.
Primer

Sequence

Application

mz3.3F

5’ATGATAATATGGCCACAACCATGGTAAGCCGATACGT3’

mz3.3R

5’GATAATTCTTAATTAATTCATCACCCAATCAGTACGTTAATTTTGGC3’

3.3 VF

5’TTAACGTACTGATTGGGTGATGAATTAATTAAGAATTATCACCGCTTCTATTCAGC3’

3.3VR

5’GGTACGTATCGGCTTACCATGGTTGTGGCCATATTATCA3’

Amplification of mazF for construction
of pcDNA3.3-mazF
Amplification of pcDNA3.3 for
construction of pcDNA3.3-mazF

3.1 mF

ATGATAATATGGCCACAACCATGGTAAGCCGATACGT-3’

Amplification of mazF for construction

3.1mzR

5’GATAATTCTTAATTAATTCATCACCCAATCAGTACGTTAATTTTGGC-3,

of pcDNA 3.1-IRES-mazF

3.1VF

5’TTAACGTACTGATTGGGTGATGAATTAATTAAGAATTATCACCGCTTCTATTCAGC-3’

Amplification of pcDNA3.1(+) IRES

3.1VR

5’-GGTACGTATCGGCTTACCATGGTTGTGGCCATATTATCA-3’

for pcDNA 3.1-IRES-mazF

G-in-F

5′-TTGGACCCTCGTACAGAAGC TAATACG-3′

Amplification of mazF and GFP (for

G-in-R

5′- T120-CTTCCTA CTCAGGCTTTATTCAAAGACCA-3′

preparation of IVT template)

IZ-in-F

5’-AACCCACTGCTTACTGGCTTATCGAAATTAATACGAC-3’

Amplification of IRES-mazF and IRES-

IZ-in-R

CCCTCTAGACTCGACTCTAGAAAGTGTCTCATGCCGG-3

GFP (for preparation of IVT)
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Table 3.2. The in vitro transcription reaction (Life Technologies, USA)
Component

Concentration for each reaction

ATP solution
CTP solution
GTP solution
UTP solution
Anti-Reverse Cap Analog
10X reaction buffer
Linear template (PCR product)
Enzyme

7.5 mM
7.5 mM
2.5 mM
7.5 mM
1mM
1X
0.1-1 μg
>500 units (Based on the manufacture instructions)

Cell Culture
Human embryonic kidney 293 cells (ATCC® CRL-1573) and human MCF7 breast
(ATCC® HTB-22) adenocarcinoma cells were maintained in Dulbecco’s Modified Eagle’s
medium (DMEM) with high glucose and 2mM L-glutamine. AGS gastric (ACR-1739)
adenocarcinoma cell lines were grown in F12K medium, while HT29 colorectal
adenocarcinoma cell lines (ATCC® HTB-38) were cultured in McCoys 5A medium. All
the media were supplemented with 10% fetal bovine serum (Atlanta Biologicals, USA) and
1% penicillin/streptomycin. Cells were maintained in fresh medium every 2 days at 37ºC
with 5% CO2.

Transfection
All cell lines were seeded in concentrations of 5x105 cells per well and 2.5x104
cells per well in 6-well and 96-well plates, respectively. The cells were incubated overnight
at standard conditions, and transfection procedures were performed the following day.
According to the manufacturer’s instructions (ThermoFisher Scientific, USA),
Lipofectamine™ MessengermAX™ Transfection was diluted and incubated in

58

OPTI-MEM (ThermoFisher Scientific, USA) for 10 minutes, followed by the
incubation of mRNA and Lipofactamine for 5 minutes at room temperature.
The Lipofactamine-mRNA complex was added to cells at 80-90% confluency.

Cell Viability Assay
The viability of transfected cells was analyzed by trypan blue exclusion. The cells
were seeded in 6-well plates and transfected with mazF mRNA the following day. The
transfected cells were trypsinized and counted using a hemocytometer.

Cell Proliferation Assay
The toxicity of mazF mRNA on different cell lines was determined using MTT
assay analysis (Promega, USA) according to the instructions for the CellTiter NonRadioactive Cell Proliferation Assay.

Immunofluorescent Microscopy
The activation of caspase -3 and -7 was visualized under immunofluorescence
microscopy by using Image-iT LIVE Red Caspase -3 and -7 Detection Kit (Molecular
Probes; Invitrogen). Cells were plated at a concentration of 2.5x104 cells per well in 96well plates, and the impact of MazF in apoptotic induction was detected after 24 (For MCF7
and AGS cells) and 48 hours (For HT29 cells) post-transfection.
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Caspase Activity Assay
Caspase -3 and -7 activity was measured using Caspase-Glo® 3- and -7 Assay
(Promega, Madison, USA). In accordance with the manufacturer’s protocol, a luminogenic
caspase -3 and -7 substrate containing the tetrapeptide sequence DEVD was added to each
well in white-walled 96-well plates and incubated at room temperature for 1 hour. Each
sample was analyzed with a plate-reading luminometer.

Western Blot Analysis
Western blot assays were conducted with the anti-cleaved PARP monoclonal
antibodies and anti-actin monoclonal antibodies (Cell Signaling Technology, Inc., USA).
The transfected cells in 6-well plates were suspended in lysis buffer (20 mM Tris-HCl (pH
7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) (Cell
signaling technology, Inc., USA) and incubated on ice for 5 minutes. The lysates were
centrifuged at 14000 X g, at 4ºC for 10 minutes. The proteins present in the lysate were
separated on a 10% SDS-PAGE gel and then transferred to a PVDF membrane (BioRAD,
USA) via a semi-dry electroblotting machine. Subsequently, the membranes were blocked
(TBE, 5% dry milk powder, 0.1% Tween-20) for 1 hour at room temperature and incubated
with antibodies overnight at 4ºC. Horseradish peroxidase-conjugated secondary antibody
and chemiluminescence substrate (Cell Signaling Technology, Inc., USA) were used to
visualize actin and any cleaved PARP.
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Nascent Protein Synthesis Assay
The transfected cells were prepared for analysis using the Click-iT Plus OPP
Protein Synthesis Assay Kit (Alexa Fluor 594 picolyl azide, Invitrogen). Cells were stained
with 20 uM Click-iT OPP according to the manufacturer’s instructions, with a slight
modification: cells were fixed using 4% paraformaldehyde for 15 minutes instead of the
recommended 3.7% formaldehyde. Following staining, samples were imaged using a GE
IN Cell Analyzer 2500HS. Samples were then analyzed using GE InCarta software (version
1.5). For analysis, a mask was created using HCS Nuclear Blue Stain. Per the
manufacturer’s instructions, the only fluorescence signal from Alexa Fluor 594 (red) that
was detected within the Nuclear Blue mask was recorded as nascent protein synthesis.
Therefore, only fluorescence intensity in this region was reported.

Statistical Analysis
All experiments were conducted in triplicate. Data are shown as the
mean ± standard deviation. The data were analyzed through the student’s t-test. The
difference was considered as statistically significant if P< 0.05.
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Results
mazF mRNA Structure
mRNA therapy is an attractive approach for delivering genetic constructs into cells
to combat or cure a disease. mRNA therapy owes its success to its superior transfection
and expression efficiency, simplicity, and safety profile [127]. These advantages led us to
explore whether mRNA delivery could be a suitable tool to transfer mazF mRNA, as a
ribonuclease, into cancer cells. To this end, a T7-mazF construct (pT7-mazF) was designed
(Figure 3.1a). To compare the efficacy of cap-dependent and IRES-dependent translation
of mazF mRNAs for in vitro transcription purposes, we developed a pT7-IRES-mazF
plasmid (Figure 3.1b). To investigate the impact of the Kozak sequence on mazF mRNA
translation, pIRES-mazF-II was constructed (Figure 3.1c). GFP mRNAs in cap-dependent
and IRES-dependent translation manners were synthesized from pcDNA3.3_eGFP and
pcDNA3.1(+) IRES, respectively (Figure 3.1d and e). Additionally, a number of mRNAs
lacking one or more important structural elements, such as a cap, an IRES, poly-As, or
Kozak sequences, were generated and then subjected to transfection. Since mRNA’s
structural elements and codon compositions play important roles in translational efficiency,
we investigated whether ACA-less mazF mRNA would be translated effectively in
mammalian cells.

Our results indicated that the capped-polyadenylated mazF or IRES polyadenylated
-mazF could be translated in cells, while omission of any one of these mRNA structural
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elements, i.e. cap/IRES or poly-As, was enough to block MazF expression. As detailed in
Figure 3.1, the mRNAs lacking cap or poly-As were not translated under these in vitro,
However, the lack of Kozak did not have any significant impacts on the expression of MazF
protein.
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Figure 3.1.a. pcDNA3-3-mazF map
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Figure 3.1.b. pcDNA 3.1-IRES-mazF
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Figure 3.1.c. pT7-IRES-mazF map
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Figure 3.1.d. pcDNA3.3.-eGFP map (Addgene, USA)
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Figure 3.1.e. pcDNA3.1(+) IRES-GFP (Addgene, USA)

Figure 3.1. a-e. DNA temples used for in vitro transcription purposes. a) pcDNA3-3-maz was used to
develop capped mazF mRNA, b) pcDNA 3-1-IRES-mazF designed for generation of IRES-mazF, c)
mRNA synthesized from pT7-IRES-mazF does not have a Kozak fragment in its sequence, d) and e)
pCDNA3.3-eGFP and pCDNA3.1(+) IRES-GFP were used to generate cap and IRES-GFP mRNAs,
respectively.

In mammalian cells, synthesized RNAs undergo nucleoside modifications that
distinguish them from exogenous RNA [92]. Kormann et al. suggested that the replacement
of one of four basic nucleoside triphosphates with a modified nucleotide blocks the
interaction of mRNA with TLR3, TLR7, TLR8, and RIG-1, which leads to the elimination
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of the immunogenicity of exogenous mRNA [128]. In comparison to other modified
nucleotides, the incorporation of pseudouridine into synthesized mRNA has been reported
to yield a higher level of mRNA translation and increases the safety profile of such RNA
therapies [129]. Therefore, mazF transcripts containing pseudouridine were also evaluated
for their translational ability in mammalian cells (Figure 3.2). In order to contribute MazFmediated cell death to translation of transfected mazF mRNA, antisense mazF RNAs,
complementary to the 5’ end of mazF mRNA, were co-transfected into AGS cells. Our
results indicated that the partially double-stranded mazF mRNAs-antisense hybrid was
sufficient to block effective translation of mazF mRNA, resulting in reduced cell death
compared to cells transfected with mazF mRNA alone (Figure 3.2).
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Figure 3.2. The impact of mRNA structural elements on MazF translation. mazF mRNA containing a cap or IRES and Poly-As were transfected, and
MazF protein mediated death of AGS cells, while mazF deficient for cap or Poly-As failed to induce cell death. The co-transfection of mazF mRNA and
its related antisense fragments led to increased AGS cell survival in contrast to transfection of mazF mRNA alone.
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MazF-Mediated Death in Cancer Cells
To examine the expression of mazF mRNA and GFP mRNAs in cancer cells, four
versions of mazF and GFP mRNA were synthesized: capped and Poly-As, capped and
Poly-A mRNA carrying pseudouridine, cap-independent and Poly-A mazF mRNA, and
Poly-A cap-independent mRNA with pseudouridine. The mRNAs were then
dephosphorylated with Antarctic phosphatase to prevent mRNAs from being recognized
by RIG-1, which is a sensor for viral RNAs. HEK293, MCF7, AGS, and HT29 cells were
then transfected with these mazF or GFP mRNAs. Monitoring transfected cells by
fluorescence microscopy showed that cells began to express GFP 6 hours after transfection.
Cells exclusively translated the capped and polyadenylated GFP mRNA or mRNAs
possessing an IRES sequence and poly-A tail (Figure 3.3). However, the fluorescence
intensity of the IRES-dependent GFP was lower than that of capped GFP. GFP supported
by IRES was expressed only in the AGS cell line, while the expression of IRES-GFP was
not detectable in HT29, MCF7, and HEK293 cell lines.

Following the transfection, our results demonstrated that the expression of mazF
mRNA in cells arrested cell proliferation and led to a progressive cytopathogenic effect
(CPE) over the course of transfection (Figure 3.4). Significantly, HEK293 and AGS cells
underwent extreme morphological change 19 hours after transfection, while MCF7 and
HT29 cells had a severely reduced number of attached cells 24 and 36 hours post
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transfection, respectively, suggesting that MazF proteins were able to induce death in
cancer cells.
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a. MCF7

b. HT29

c. AGS

d. AGS (transfected with IRES-GFP)

e. HEK293

f. Non- transfected cells

Figure 3.3. a-f. The expression of GFP mRNA in cancer cells 24 hours post transfection; in panels a), b),
d) and e), cells were transformed with capped GFP-Poly-A mRNAs, while in panel c), AGS was
transfected with IRES-GFP mRNA.
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a1. MCF7- control

2a. MCF7- transfected by mazF

b1. HT29- control

b. HT29- transfected with mazF

c1-HEK293- control

c2. HEK293- transfected by mazF

d1-AGS- control

d2. AGS- transfected by mazF

(Related to Figure 3.4 on the next page).
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f. AGS transfected by GFP mRNA

e. AGS transfected by antisense RNA
Fragments+mazF

Figure 3.4. a-f. The morphological changes that occured in cancer cells after transfection of cells with mazF
mRNA

The viability of MCF7, AGS, and HT29 cells expressing mazF mRNAs was
determined by trypan blue exclusion. As illustrated in Figure 3.5, when the cells were
transfected with one of the four types of mRNA mentioned above, the viability of cells was
drastically reduced. Cell viability was also determined by the MTT assay, and its results
showed that the expression of MazF protein hampers cell metabolic activity and increases
the number of dead cells (data not shown). These data confirm that the expression of the
MazF protein induces death in the examined cancer cell lines.
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a. Transfected MCF7 cells with mazF mRNA

(Related to Figure 3.5 on page 90)
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b. Transfected AGS cells with mazF mRNA

(Related to Figure 3.5 on page 90).
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IRES-mazF

IRES-mazF+ Psudo
U

120.0

Percentage of viable cells

100.0

80.0

60.0

48 h
72h

40.0

20.0

0.0
Control

Negative
control

GFP

mazF

mazF+ Psudo
U

IRES-mazF

IRES-mazF+
Psudo U

c. Transfected HT29 cells with mazF mRNA
Figure 3.5. a-c. The expression of MazF results in the significant reduction in cell viability in transfected cells. a) MCF7, b) AGS, and c) HT-T9. The
difference was considered as statistically significant if P< 0.05 ( ). NS: Not Significant
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MazF-Mediated Apoptosis in Cancer Cells
During stationary phase, the MazF protein mediates cell death in E. coli cells by
cleaving cellular mRNAs at ACA sequences [16]. According to the findings of Shimazu et
al., MazF protein has a similar ribonuclease function in the human HEK293 cell line, which
stimulates the occurrence of apoptosis. To validate the induction of apoptosis in different
cancer cells, we examined whether activated caspase -3 and -7 were present in the
transfected cells. The caspase -3 and -7 detection assay contains aspartic acid-glutamic
acid-valine-aspartic acid (DEVD), a caspase substrate that has a high affinity for activated
caspases. Our results showed that the expression of MazF caused apoptosis reactions in
MCF7, AGS, and HT29 cells and exhibited MazF-mediated apoptosis 12, 18, and 36 hours,
respectively, post transfection. In comparison to other cell lines, HT29 was less susceptible
to MazF proteins. Additionally, the activity of caspase was quantified in the various cell
lines (Figure 3.6 and Figure 3.7). Furthermore, we investigated whether cleaved PARP, a
marker of cells undergoing apoptosis, was present in the cell lines translating mazF mRNA.
Except for MCF7, each cell line revealed a detectable level of cleaved-PARP at various
hours post transfection. While AGS showed the highest level of cleaved-PARP 18 hours
post transfection (Figure 3.9), HT29 released the cleaved-PARP 48 hours post transfection.
Altogether, these results demonstrated that MazF could induce apoptosis in cancer cells.
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a. MCF7

b. AGS

c. HT29

d. Control (Normal cells)

Figure 3.6. a-d. The activation of caspase -3 and -7 in cancer cell lines: a) MCF7, b) AGS, c) HT29, and
d) Control. Fluorescent cells are the indication of the activation of caspase -3 and -7.
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a) Detection of caspase -3 and -7 in MCF7 cells transfected with mazF mRNA

(Related to Figure 3.5 on the next page).
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b) Detection of caspase – 3 and -7 in AGS cells transfected with mazF mRNA

(Related to Figure 3.57 on page 85).
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c) Detection of caspase – 3 and -7 in HT29 transfected with mazF mRNA

Figure 3.7. a-c. The induction of MazF resulted in the activation of caspase in a) MC7, b) AGS, and c) HT29

83

100 kDa
75 kDa

a. cleaved -PARP

b. -actin

Figure 3.8. The presence of cleaved-PARP in transformed cell lysates after 18 hours of induction of MazF
in AGS. Ladder: Precision Plus protein™ (BioRAD, USA).

MazF-Mediated Inhibition of Protein Synthesis in Cancer Cells
In E. coli, the activation of MazF protein leads to inhibition of protein synthesis
through digestion of cellular mRNA [16]. Hence, we evaluated the inhibition of protein
synthesis by MazF in MCF7 and AGS cell lines via quantifying mRNA translation on a
single-cell basis. In this assay, O-propargyl-puromycin (OPP) was incorporated into de
novo peptide chains, and the generated chain was labeled by photostable Alexa Fluor®
dye. Hence, fluorescence signals were used to measure nascent protein synthesis. As
illustrated in Figure 8, MazF proteins significantly blocked synthesis of new proteins in the
cells. Thus, our results confirmed the translational interference role of MazF in the
examined cell lines.
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In E. coli, MazF cleaves mRNA at ACA sequences. GFP mRNA has 21 ACA
sequences in the codon region. The co-transfection of mazF mRNAs with pcDNA3.3-eGFP
resulted in the decrease of GFP signal in transfected cells (

Figure 3.10). This observation indirectly confirmed that MazF is able to degrade
mRNAs and eventually block protein synthesis in transfected cells.

a1. MCF7 cells Transfected with mazF mRNA

a3. Cells transfected with mazF mRNA

a2. Control cells (MCF7)
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(Related to Figure 3.9 on the next page).

b1. Transfected AGS with mazF mRNA

b2. Control cells (AGS)

b3. AGS transfected with mazF mRNA

Figure 3.9. a-b. MazF blocked protein translation in a) MCF7 and b) AGS cells transfected with mazF
mRNA. The reduction of fluorescence (Red signals) indicated the inhabitation of nascent protein in
transfected cells. The nucleases were stained by NuclearMask Blue stain (ThermoFisher Scientific, USA).
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a. HEK293 transfected with pcDNA3.3eGFP

b. Co-transfection of cells with mazF
mRNA and pcDNA3.3-eGFP

Figure 3.10. MazF is able to cleave mRNA at ACA sequences. A few HEK293 co-transfected with GFP
plasmid and mazF mRNA expressed GFP signals.

Discussion
Even with recent advancements in the medical field, cancer remains one of the main
concerns of recent centuries. Introduction of novel therapies can bestow hope to many
patients worldwide. As a new treatment, ribonuclease seems to be a promising treatment
in cancer therapy at the level of transcription and translation. However, within a short
period of time, it became evident that certain ribonucleases, due to their instability, the lack
of cytotoxic or cytostatic activity, and the presence of ribonuclease inhibitors (RI) within
cells, are poor candidates for cancer therapy purposes [130]. MazF is a small and stable
ribonuclease in bacterial cells that cleaves mRNAs, tRNA, and rRNA at ACA sequences.
Under normal conditions, MazF binds a small, labile protein, MazE, and remains nontoxic
in the cells. While under stressful conditions, MazE is degraded, but MazF arrests cell
proliferation and induces death within bacterial cells [131]. Thus, the mRNA interference
activity of MazF and the absence of a MazF inhibitor in mammalian cells encouraged us
to investigate its potential application in cancer therapy. Shimazu et al. showed that MazF
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is able to halt the growth of and induce apoptosis in T-REx-293 cells, a human kidney cell
line. Given that cancer is a heterogeneous group of diseases with various sensitivities to
different treatments, we examined the impact of MazF on the growth and viability of three
cancer cell lines, MCF7, HT29, and AGS, which carry different mutations and exhibit low
sensitives to traditional cancer treatments.

In this study, we demonstrated that the delivery of mazF mRNA into cancer cells
enhances translation of the encoded protein. mRNA is an attractive candidate in non-viral
gene therapy due to its ability to be active in the cytosol without entering the nucleus.
However, mRNA lability has always minimized the advantages of mRNA-based therapy.
In order to address this concern, we studied the necessity of the main structural elements
of mRNA to boost the translation efficiency of MazF in in vitro cell line conditions. Our
results demonstrated that the presence of Cap/IRES and poly-A elements enables the
translation of the encoded protein in cells. We also synthesized and delivered GFP and
mazF mRNA into HEK293, MCF, AGS, and HT29 cell lines. mazF mRNA deficient for
caps or Poly-As resulted in no induction of death in transfected cells. These results may
suggest a synergy between the cap structure and poly-A tail on translation efficiency, a
finding reported by various researchers [132-135]. This cooperation stems from mRNA
circulation, where the cap-eIF4E-eIF4G-PABP-poly-A complex hampers the function of
exonucleolytic nucleases in order to degrade mRNAs [95].
The 5′ ends of eukaryotic mRNAs contain a methylated m7GpppN cap structure
that is crucial for mRNA splicing, stabilization, transport, and translation. In IVT reactions,
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the cap structure is linked to the synthesized mRNA through an enzymatic reaction.
However, this capping process caps either the 5′ side or both ends of the mRNA, rendering
half of the synthesized mRNAs nonfunctional [95]. Recently, several cap analogues have
been designed to optimize the capping process in in vitro conditions. One example of these
cap analogs is the anti-reverse-cap analogue (ARCA), which contains a methylated 3’-OH
group that forces ARCA to localize in the proper orientation [95].

Although the cap is a fundamental element in mRNA stability and translation, some
viral and cellular mRNAs possess internal ribosome entry sites (IRES) that carry out their
translation in a cap-independent manner. IRES sequences directly recruit ribosomes and
start translation at either a non-AUG codon or an overlapping +1 frame gene [136]. The
discovery of IRES has led to an exciting path in cancer therapy. This element enables
researchers to design bicistronic, tricistronic, or tetracistronic operons encoding two or
more genes under the control of a single promoter. Here, we recruited the IRES sequence
from encephalomyocarditis virus (EMCV) RNA to synthesize uncapped mRNAs. We then
compared the expression of capped and capped-independent mRNA in cell-culture
systems. As mentioned previously, both IRES-mazF and capped mazF were expressed in
the examined cell lines in a time-dependent manner. However, it appears that each cell line
differs in expression of capped and IRES-dependent mRNAs, and AGS cells are more
likely to express IRES-GFP than other cell lines. This indicates the probability that the type
of mRNA and cell line has significant influences on the expression of capped and cappedindependent mRNAs. Our results of transfected IVT mRNA in cells concur with that of
other research groups [126, 137, 138]. Avci-Adali et al. reported that, in spite of the high

89

transfection efficacy, human endothelial cells and BJ human foreskin fibroblasts express
fewer copies of capped GFP proteins in comparison to HEK293 [126].

Another problem that overshadows the advantages of the IVT mRNA technique is
mRNA immunogenicity. Several investigations have indicated that certain innate immune
receptors such as Toll-like receptors (TLR)3, TLR7, TLR8, and retinoic acid-inducible
gene I (RIG-I) may be stimulated by exogenous RNA. The incorporation of modified
nucleosides, e.g. pseudouridine or 2-thiouridine (s2U) in IVT mRNA, and the elimination
of 5′ triphosphates from synthesized mRNA can suppress the activation of Toll-like
receptors and RIG-I [126, 139]. Previous research showed that association of
pseudouridine in mRNA structures significantly enhances the translation efficiency of the
encoded proteins when compared to mRNAs possessing unmodified uridines [126, 140,
141]. This difference stems from the diminished activity of protein kinase ribonuclease
(PKR) in the presence of mRNAs that contain modified nucleotides [139]. It seems that
pseudouridine has the ability to enhance stability and boost the expression of IVT mRNAs
in comparison to other modified nucleotides [141]. Our results, however, slightly varied
from those of previous studies. Our data showed that the presence of modified nucleotides
in the IRES-GFP structure did not lead to an increased expression of encoded proteins in
cells. Our data also highlighted the role of each cell line in the expression of IVT mRNAs
containing either modified or non-modified nucleotides.

As a part of their defense responses, eukaryotic and prokaryotic cells have the
capability to degrade mRNA and subsequently suppress protein synthesis. For example,
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when bacteria are exposed to harsh conditions (e.g. extreme amino acid starvation or
antibiotic-blocked transcription or translation), they use MazF proteins to cleave mRNAs
and therefore block protein synthesis [36]. In mammalian cells, some of the host antiviral
responses that lead to inhibition of protein synthesis and eventually to induction of
apoptosis in virus-infected cells include the interferon response, RNaseL-mediated
degradation of 28S and 18S ribosomal RNAs, and the activation of protein kinase-R.
However, cancer has a high addiction to protein synthesis that can be targeted by
ribonuclease-based therapy [142]. We analyzed the impact of MazF proteins on inhibition
of protein synthesis, which results in the induction of apoptosis in MCF7 and AGS cell
lines. In this study, nascent protein synthesis was determined through measuring the
incorporation of O-propargyl-puromycin (OPP) into newly synthesized proteins. Our
observations confirmed that the overexpression of MazF leads to a drastic drop in the levels
of protein translation in the examined cell lines. These results are consistent with the study
conducted by Shimazu et al. which demonstrated that the level of protein synthesis was
reduced in T-REx-293 cells 24 hours post transfection with MazF mRNA. In addition, our
results suggested the reduction of protein synthesis mediated by MazF was cell linedependent.

In mammals, the inhibition of protein synthesis leads to apoptosis and cell death,
although the exact mechanisms remain unknown [143]. Here, our data illustrated that MazF
not only stopped the proliferation of cells but also significantly reduced the number of
living cells 18 to 24 hours post transfection in tested cell lines. In order to confirm the
occurrence of apoptosis, the activation of caspase -3 and -7 and the presence of caspase 3’s
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substrate was evaluated in transfected cells. Our observations suggested that in the presence
of MazF, the level of caspase -3 and -7 significantly increased, and apoptosis took place in
the cells. These data confirm the antiproliferative action and apoptotic ability of MazF in
cancer cells. Interestingly, MazF was able to induce apoptosis in MCF7 cells that are
supposedly apoptosis-resistant. These cells are deficient for caspase-3 and also are resistant
to ionizing radiation (IR)-induced apoptosis [144]. Essman et al. demonstrated that the
exposure of MC7 to methylxanthine caffeine and the staurosporine analogue UCN-01 did
not lead to the activation of the initiator caspase -9, and the cells then remained resistant to
apoptosis [144]. Therefore, according to our results, MazF may serve as a suitable
therapeutic candidate against MCF7. As we have demonstrated, MazF successfully
induced death in AGS and HT29 cell lines. These cell lines have been reported to possess
long non-coding RNA GACAT1 (lncGACAT1) and long non-coding RNA (lncRNA)
Gas5, respectively, that stimulate cell proliferation and invasion [145, 146]. These noncoding RNAs contain several ACA sites in their sequences that potentially make the noncoding RNAs more vulnerable to the action of MazF.

In conclusion, we described the use of MazF, a bacterial ribonuclease, to induce
apoptosis in three different cell lines. We also investigated the influence of IRES, a cap
structure, and the incorporation of modified nucleotides on the expression of the encoded
protein. Our results showed that although cell lines have a varying preference for
translation of the delivered mRNAs, the delivered mazF mRNA was expressed, and the
MazF protein was able to inhibit de novo protein translation. Thus, it seems MazF has a
great potential to serve as a therapeutic agent for cancer therapies.
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CHAPTER FOUR
4.

Listeria monocytogenes-Mediated Delivery of mazF mRNA into
Cancer Cells
Introduction
Gene Delivery and Vectors
Gene therapy is described as the delivery of genetic information to cells intended

to treat or alleviate a patient’s disease by synthesizing a therapeutic protein or genetically
engineering the cells [147]. For this purpose, genetic materials including genes, gene
segments, or oligonucleotides are transferred into patient cells through in vivo or ex vivo
methods. In vivo practice, cells inside the body are directly targeted by a gene delivery
system such as intradermal injection or intravesical therapy. While in ex vivo approaches,
the expelled cells from tumors are genetically modified at a controlled microenvironment
and then transplanted to the patient [148].

Deactivation of oncogeneses or replacement of defective tumor suppressor genes
have always been a challenge in cancer therapy. Delivery of transgenes into target cells has
opened a new door to change or modify malfunctioning genes or phenotypes of cells
transiently or permanently. In gene therapy, normal cells, cancerous cells, immune-
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mediated cells, or pluripotent stem cells can be a host for transgenes. Once transferred
inside cells, the delivered transgenes induce death in cancer cells or correct their cellular
functions while protecting normal cells from drug-induced toxicities or activating immune
cells to eliminate cancer cells [148]. However, the success of gene therapy relies on the
specificity of vectors to deliver DNA or RNA constructs into tumor cells or normal cells.
In the past, several non-biological (chemical and physical methods of introducing plasmid
DNA to mammalian cells) and biological (viruses and bacteria) approaches have been
applied against cancer cells [123, 149-151].

The advent of recombinant DNA technology, the advances in the design of gene
delivery systems, and the accumulation of knowledge on the genetic basis of many diseases
paved the way for the emergence of gene therapy against cancer. In 1990, the first gene
therapy trial was conducted against severe combined immunodeficiency disorder in a
patient. In spite of many disappointments, challenges, and barriers, several successful
clinical trials and the production of many innovative genetic medicines have strengthened
the evidence for the effectiveness of gene therapy in treating serious diseases such as cancer
[2,3].

Gene therapy approaches halt or prevent a pathological process through gene
addition, gene correction/alteration, or a gene silencing process [152]. Gene addition is
applied to introduce a therapeutic protein into deficient cells, while gene
correction/alteration is used to modulate genomic sequences to correct inoperative genes.
Gene knockdown inhibits or downregulates gene expression or translation by RNA
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interference systems or micro RNA (miRNA)-mediated gene systems. Other nucleic-acidbased tools such as RNA aptamers, upregulating small RNAs, and non-coding genes for
protein functional modifications have recently synched to gene therapy attempts [152].

In spite of spectacular advances in designing vector systems, gene delivery is still
confronted with numerous obstacles. One of the main barriers is the accessibility of vectors
to the target sites. Host parameters such as vascular supply and endothelial barriers and
features of vectors, e.g. size, their ligands, and mechanisms of vector uptakes and toxicity
of vectors, affect the distribution of vectors in targets. When endosomes and nuclear
membranes are the most common impediments for success of non-viral vectors, instability
and the massive size of viral vectors have remained hurdles for viruses to translocate from
the cytoplasm to the nucleus. The cell division rate can influence the existence of vectors
in targets. Episomal vectors only survive in quiescent tissues, such as brain, heart or, liver,
while these vectors will be diminished in rapid turnover cells such as hematopoietic cells.
Although they survive longer in dividing cells, integrational vectors might stimulate
mutations in adjoining genes. Additionally, the integrity of vectors and transgene products
can be hindered by the host immune response [152].

Transgenes can be exploited for therapeutic and potentially preventive purposes for
many diseases. However, instability and the non-specific nature of transgenes and low
delivery efficacy have raised doubts on the feasibility of the direct delivery of transgenes.
While advances in nucleic acid modifications can increase the half-life of transgenes, the
low specificity and cellular uptake efficiency remain important challenges in transferring

95

naked transgenes. The advent of gene delivery vehicles (GDV) has overcome some of these
limitations and also protected the delivered materials from the host immune systems [153].
GDV are traditionally categorized into two groups, i.e., non-biological and biological
vectors. Non-biological vectors are defined as DNA plasmids that can be directly
transferred to the targets or in association with chemical or physical delivery systems. The
safety profile and economic advantages, e.g. cost-effectiveness and ease of production, of
non-biological vectors have enabled them to be potential suitable vectors in gene therapy.
However, the low delivery efficacy and specificity and perseverance of non-biological
vectors have cast a shadow over their advantages for several years [154]. Recently, the
advances in improvement of delivery efficacy have led to growing inclinations to employ
non-biological vectors in clinical trials. These vectors are generally suitable for delivery of
oligodeoxynucleotides or related molecules synthesized chemically, plasmid DNA,
ribozymes, siRNA, and mRNA into a target. Non-biological vectors can be divided
traditionally into two main groups: physical delivery systems such as a needle, ballistic
DNA, electroporation, sonoporation, photoporation, magnetofection, and hydroporation;
and chemical systems, e.g. calcium phosphate, cationic lipids, and lipid nanoemulsions
[154].

Biological liposomes, which are able to evade immune systems, are one of the nonbiological vectors extracted from human cells. However, technical limitations such as
difficulties in harvest time and maintaining the resource cells have obstructed the liposome
applications in gene therapy [154].
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Biological vectors contain a range of microorganisms with abilities to infect host
cells and to escape or be tolerated by immune systems, phagocytic cells, and exosomes
[153]. The ideal features of GDV biological vectors include possessing appropriate
capacities for their payload, ability to escape from host immune systems, target specificity,
and high delivery efficacy. However, each biological vector is deficient in one or some of
the aforementioned ideal criterions. For example, constraints of packaging size, host range,
mutagenicity, inflammatory toxicity, and being recognized by immune systems are the
most common limitations of viral vehicles as the conventional biological GDVs. Advances
in DNA technology have already resolved some of these limitations. Insertion of a
heterologous protein on viral vectors leads to the diversity of their host ranges. Genetic
modifications on viral capsids and usage of tissue-specific promoters and enhancers might
boost the specificity of viral vehicles and their expression profiles. However, toxicity and
the stability of gene expression remain the greater challenges in the usage of viral vehicles
[155].

Viral vectors are classified into two groups: integrating vectors, e.g. gammaretroviral vectors, and lentiviral vectors, and non-integrating vectors such as adenoviral
vectors and adeno-associated virus (AAV). Compared to wild types, the modified
adenoviruses have higher tendencies to transduce dividing and non-dividing cells and
replicate in target sites. Adenoviruses also offer other advantages, such as the ease of largescale production and their abilities to carry drug or pro-drug genes. However, the
application of adenoviral vehicles has been shadowed by their capabilities to destabilize
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the carried gene, stimulate chromosomal aberration in host cells, and induce inflammatory
reactions [155, 156].

Lentiviruses contain a group of viruses with long incubation periods and persistent
infections in humans or animals. Lentiviruses have been under various genetic
modifications to develop integration-deficient lentiviruses, enhance the safety profiles of
these vectors, transduce both dividing and non-dividing cells, and possess low antivirus
immunity and low potential for genotoxicity. However, thesis non-pathogen vectors can be
transformed into a pathogenic virus such as HIV, especially in immunocompromised
individuals. The integrational nature of these vectors might increase the risk of cancer or
secondary malignancy [148].

Current advances in viral vaccines and vehicle designs have resulted in the advent
of virus-like particles (VLP) as a new class of vector. VLPs contain viral structural
proteins, while the pathogenic genes are excluded. In contrast to viral vehicles, VLPs can
be produced in yeast, insect, or mammalian cells and subjugated to harsher purification
processes. Thus, VLPs are more cost-effective and purer vehicles in comparison to viruses.
These particles can also be assembled for unusual payloads, such as modified small
interfering RNAs, with the high efficacy of transduction in vitro [5, 6]. However, the low
yield of functional VLPs and their complicated disassembly and reassembly processes have
limited their delivery applications in clinical tests. Initially, VLPs have been created to
substitute the attenuated viruses in vaccinations. This immunostimulation nature of VLPs
caused them to not be continuously administrated. The immune response against the VLP
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can clear the delivered transgenes or inhibit their functions. Thus, further attempts are
required to resolve the limitations of these newly developed GDVs [153].

Bacteriophages, as the bacterial pathogens, can be suitable vehicles in gene therapy.
These viruses are able to survive in a broad range of pH, from 3 to 11, for up to 24 hours
and against nonenzymic degradation. Unlike viruses, bacteriophages contain an extensive
packaging capacity, making them suitable candidates for delivery of mammalian plasmids
or various regions for transgenes. The ease of engineering bacteriophage coat proteins leads
to the enhancement of the safety profile of this GDV and identifies target proteins or
peptides on target surfaces. However, the unmodified bacteriophage particles can be easily
cleared by the reticuloendothelial system (RES) and degraded in the liver, spleen, and lungs
[153]. Similar to VLPs, the intrinsic immunogenic nature of bacteriophages constrains the
re-administration of vehicles, resulting in poor transfer of the transgenes into the target
sites [153].

In general, the advantages and disadvantages of each vector determine its potential
applications in cancer treatment. For example, the non-biological vectors, despite their high
safety profile and low cost, have a poor clinical efficacy in comparison to biological vectors
[157, 158]. Due to their natural life cycle and pathogenicity, viruses serve as very efficient
delivery vehicles in gene therapy. However, the use of these vectors in clinical trials is
hampered by difficulties in production, size restrictions on transgenes in some viral vectors,
anti-vector immunologic responses, the lack of viral receptors in some cancer cells, and
induction of inflammatory reactions [150, 158].
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Bacteria have unique capabilities that allow them to offer more advantages than
other vectors. Bacterial vectors can be easily engineered to be tractable and to selectively
target tumors that could be difficult or even impossible for other kinds of vectors to target
[51]. In addition, bacteria have chemotactic receptors that can sense external signals from
the local environment and then propel the bacteria to targets. For example, Salmonella
typhimurium, which possesses a TAR receptor, is able to detect aspartate secreted by viable
cancer cells while its ribose/galactose receptor directs the bacteria toward necrosis of
cancer tumors [46]. Bacterial vectors can carry and transfer toxic molecules into tumor
regions that are inaccessible to passive therapies e.g. chemotherapy. These vectors can also
provide clues about the state of the tumor, the success of localization, and the efficacy of
treatment. When combined, these characteristics help cancer therapists to administer
treatments at the right time and location [51].

Today, several strains of bacteria such as Clostridia [159], Bifidobacterium [160],
Salmonella [161], Listeria [68], Escherichia [162], Caulobacter [163], Proteus [164], and
Streptococcus [165] have been reported to exclusively accumulate in tumors. As a result,
many bacterial therapeutic strategies, e.g. bacterial replication in tumors, intracellular
plasmid transfer (bactofection), native bacterial toxicity, and combinations of other
therapies and alternative gene therapy (AGT), have been suggested as a treatment against
cancer [51, 150, 166, 167].

In AGT, bacteria remain in target tissues and produce the therapeutic polypeptide
in situ. This feature of AGT makes possible the negative regulation of gene expression

100

through antibiotics or suicide genes. In turn, this negative regulation can lead to increased
safety in AGT delivery when compared to bactofection [166]. In bactofection, eukaryotic
host cells are responsible for expression of the desired genes, while in AGT, bacteria are
responsible for expressing the gene of interest. Thus, while bactofection and AGT share
some characteristics such as transporting bacteria in the organism, the main difference
between the two therapies arises in the expression of the therapeutic genes. The overall
advantages of AGT, e.g. easy and safe delivery, convinced us to apply this approach to
deliver mazF mRNA into cancer cells [166].

In this project, we intended to enhance the safety profiles of the attenuated L.
monocytogenes strain with deleted internalin A and B (Inl AB)-expressing SPA [72] by
transferring a plasmid carrying the self-destructing L. monocytogenes lysin gene from
phage A118 (ply 118), which initiates suicide once inside the cancer cells.

Experimental Section
General Microbiology Technique
Listeria monocytogenes EGDe, an internalin A/B-deficient strain, was cultured in
Brain Heart Infusion broth (BHI) at 37°C. In order to induce prfA-regulated genes in vitro,
the culture broth was supplemented with 1% Ameberlite XAD prior to autoclavation [168].
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Construction of a T7 Expression System for mazF mRNA
Overlap Extension PCR Cloning

The ACA-less mazF was inserted under the control of a T7 promoter in pCNB1
(Figure 4.1) through overlap extension PCR. For this purpose, mazF and pCNB1 were
considered as two PCR fragments that should be ligated into a circular DNA. Hence, the
designed primers for both vector and insert shared an overlap sequence to assemble the
adjacent fragments. mazF fragments were amplified by using the forward primer (CZF)
and reverse primer (CZR), and pCNB1 was linearized by applying the forward primer
(CVF) and reverse primer (CVR). The PCR products were generated by using Q5® HighFidelity DNA Polymerase (New England Biolabs Inc., USA), and the amplification
reactions were assembled according to the company’s manual (

Table 4.2 and Table 4.3). To eliminate the plasmid templates, the PCR products were

digested with DpnI (New England Biolabs Inc., USA). DpnI has the ability to exclusively
digest E. coli Dam methylase-methylated plasmid DNA, but non-methylated PCR products
will remain intact. The DpnI digestion reaction was prepared by mixing 5-8 μl of a PCR
product with 1 μl of 10X CutSmart™ Buffer and 1 μl (20 units) of DpnI. The reaction was
incubated at 37°C for 30 minutes, followed by heat-inactivation of DpnI at 80°C for 20
minutes. The digested product was used for the NEBuilder HiFi DNA Assembly protocol
(Table 4.4). The assembled reaction was incubated at 50°C for 1 hour, and the product was
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then electroporated into E. coli DH10B competent cells. The transformed colonies were
purified and used for the purpose of plasmid extraction.

Table 4.1. List of primers for insertion of mazF fragment in pCNB1
Primers

Sequence

Application

CZF

5’-ATGATAATATGGCCACAACCATGGTAAGCCGATACGT-3’

CZR

5’CTAGTATGCATGCGGCCGCTTCACCCAATCAGTACGTTAATTTTGGCT3’

CVF

5’-GGTACGTATCGGCTTACCATGGTTGTGGCCATATTATCA-3’

CVR

5’CTAGTATGCATGCGGCCGCTTCACCCAATCAGTACGTTAATTTTGGCT3.

Amplification of
mazF gene
fragment for
construction of
pCNB-mazF
Amplification of
pCNB1 for
construction of
pCNB-mazF

Table 4.2. Q5® High-Fidelity DNA Polymerase PCR reaction assembly (New England Biolabs Inc., USA)
Component

50 µl reaction

Final concentration

5X Q5 -Reaction Buffer
10 mM dNTPs

10 µl
1 µl

1X
200 µM

10 µM Forward Primer

2.5 µl

0.5 µM

10 µM Reverse Primer

2.5 µl

0.5 µM

Template DNA

variable

< 1,000 ng

Q5 High-Fidelity DNA Polymerase

0.5 µl

0.02 U/µl

Nuclease-Free Water

to 50 µl

Table 4.3. Q5® High-Fidelity DNA Polymerase PCR protocol (New England Biolabs Inc., USA)
Cycling

Temperature

Duration

Initial Denaturation
Cyclic Denaturation

98°C
98°C

30 Seconds
10 Seconds

Annealing

50-72°C

25 seconds

Extension

72°C

20-30 seconds/kb

Final extension

72°C

2 minutes

Table 4.4. HIFI DNA assembly instruction (New England Biolabs Inc., USA).
Component

20 µl assembly reaction

Recommended DNA Molar Ratio
Total amount of fragments

vector: insert = 1:2
0.03–0.2 pmols

NEBuilder HiFi DNA Assembly Master Mix

10 µl
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Cycles

30 cycles

Deionized H2O

10-X µl

The extracted plasmid was subjected to sequence verification. Finally, the
generated plasmid was named pCNB-mazF.

pCNB-mazF contains a tetracycline resistance gene as a selectable marker. However, L.
monocytogenes as the final host of this plasmid carries the same antibiotic marker.
Therefore, the tetracycline resistance gene was substituted with a kanamycin resistance
gene through overlap extension PCR cloning. For this purpose, a kanamycin gene fragment
was amplified from pIMAK by using forward (Kan-F) and reverse (Kan-R), and the
pCNB1-mazF fragment was produced by forward primer (NBZ1-F) and reverse primer
(NBZ1-R) (
Table 4.5). The PCR and HIFI DNA assembly reaction were performed according to the
above description. The final construct was named pCNB-mz-Kn. As explained before, the
modified plasmids ultimately were electroporated into E. coli Dh10B.
Table 4.5. List of primers for insertion of Kan fragments in pCNB1-mazF
Primers

Sequence

NZB1-F

5’-GCATTCGTCTCGTTACGCATTATAAA
CCCAGCGAACCATTTGAGGTGATAGG-3’
5’GCTGACGGTAACCATAATGAGACAGAATTATGATG
ATCATATGAAACATCAGAGTATGG-3’
5’-CTGGGTTTATGATGTATTCACATTTCACCCTCCAATAATGAGG-3’

NZB1-R

5’-TGTCTCATTATATCGTTAAGGGATCAACTTTGGGAGAG-3’

Kan-F
Kan -R

Application
Amplification of
kanamycin gene
fragment
Amplification of
pCNBZ-1 for
construction of pCNBmz-Kn

Preparation of Competent Cells from Listeria monocytogenes (Lm)
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Lm competent cells were prepared by following the protocol previously described
[169]. Lm strains EGDe were cultured in 50 ml BHI overnight at 37 ºC. The culture was
then diluted 1:100 in 500 ml of BHI supplemented with 500 mM of sucrose. At this point,
the optical density at 600 nm (OD600) was in the 0.01 to 0.02 range. The diluted culture
was re-incubated at 37ºC and 250 rpm until OD600 reached 0.2 to 0.25. Consequently, the
culture was cured with 10 μg/ml of freshly prepared ampicillin and incubated for another
2 hours to double the cell population. The culture was then placed on ice for 10 minutes,
followed by centrifugation at 5,000 ×g for 10 min at 4°C. The cell pellet was then washed
by ice-cold sucrose-glycerol wash buffer (SGWB) (10% glycerol, 500 mM sucrose; pH
adjusted to 7 with 100 mM NaOH; filtersterilized) three times. Subsequently, 10 μg/ml of
filter-sterilized lysozyme (40,000 to 45,000 U per mg; hen egg white; crystallized three
times; Sigma) was added to the cells and incubated at 37°C for 20 min. The Cells were
pelleted at 3,000 ×g for 10 min at 4°C and washed by SGWB. The final pellets were
dissolved in the same buffer and dispensed into 50 μl centrifuge tubes. The competent cells
were stored at −80°C [169].

Electroporation of Lm cells

The electrotransformation of Lm was performed by following the protocols previously
described [169]. A 50-μl aliquot of electrocompetent cells was incubated with 1μg of
plasmids and placed on ice for 5 minutes. The contents were pipetted to a chilled 1-mm
electroporation cuvette (Bio-Rad) and electroporated at 10 kV/cm, 400 Ω, 25 μF , and 7
minutes time constant. Immediately, 1ml of room temperature BHI+500 mM sucrose was
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added to the cuvette. The cells were incubated at 30°C for 1.5 h and cultured on BHI agar
possessing antibiotics [169].

Functionalization of Bacterial Cells with Anti-HER Antibodies
The Lm functionalization was performed by following the protocols previously
described [168], with several modifications in preparation and concentration of cells. Lm
cells were cultured in 20 ml BHI overnight at 37ºC. The culture was then centrifuged at
5000 ×g for 10 minutes at 4°C. The pellet was washed twice and re-suspended in PBS
(pH=7). The optical density at 600 nm (OD600) of bacteria and cell numbers were measured
by using a BioRAD spectrophotometer. Bacterial cells were diluted in PBS for a final
concentration of 109 cells in 100 μl PBS, and the contents were inoculated with 4-5 μg of
antibody for 1 hour at 23°C under vigorous shaking (500 rpm). Afterward, 900 μl PBS was
added to the bacterial cells, and the contents were centrifuged at 16000 ×g for 2 minutes.
The supernatant was discarded, and the bacterial cells were resuspended in 1 ml PBS.

In this project, Human ErbB2/Her2 Alexa Fluor® 488-conjugated Antibody (R&D
systems, USA) and Anti-HER2 (Trastuzumab) Humanized Antibody (Bio Vision, USA)
were used to functionalize Lm cells. Mouse IgG2 Alexa Fluor® 488-conjugated isotype
control (R&D system, USA) was used as the negative control in the experiments.

To confirm the presence of SPA, the bacterial cells coated with Human
ErbB2/Her2 Alexa Fluor® 488-conjugated Antibody (R&D systems, USA) were
visualized under immunofluorescent microscopy.
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Eukaryotic Cell Culture
Human gland/breast SKBR3 (ATCC® HTB-30™) adenocarcinoma and mouse
gland T41 carcinoma (provided by Dr. Rice’s lab, Clemson University) were cultured in
DMEM/F12 medium (ThermoFischer Scientific, USA) and maintained at cultural
conditions. The media were supplemented with 15% FCS. Cells were passaged at 80-90%
confluency at 1:2 to 1:6 ratios. T41 cells were cultured in McCoy’s medium containing
10% FCS and then placed at 37°C under 5% CO2 atmosphere.

Immunofluorescence Staining
The cell staining procedure was performed based on R&D system’s suggested
protocol with few optimizations in the buffer amounts and incubation time. At least 16
hours prior to infection, cells were seeded in an 8-well chamber slide at 8x104 cells per
well. When cells reached 60-70% confluency, wells were washed with wash buffer. The
cells were incubated with 200 µL Donkey serum, the blocking buffer, for 45-60 minutes at
room temperature to block non-specific interactions with antibodies. The blocking buffer
was then discarded, and the cells were incubated with 5 µg of Alexa Fluor® 488conjugated Antibody (R&D systems) at room temperature for 1 hour. Cells were
consequently washed twice in 200 µl of wash buffer and visualized under the fluorescence
microscope.

The infection of cancer cells with Lm was performed as previously described with
some modifications [168]. With at least 16 hours of preincubation, SKBR3 and 4T1 cells
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were seeded at 3x105 cells/well in 12-well plates. First, each well was washed with 1ml
serum-free medium followed by the addition of bacteria in the same medium. The infection
step was performed for 1 hour at culture condition. Furthermore, the medium containing
bacteria was substituted with 1 ml fresh culture medium supplemented with 100 µg/ml
gentamicin, and cells were incubated with the antibiotic for 1 hour at 37°C.

To evaluate the number of internalized bacteria at the early invasive stage,
eukaryotic cells were washed five times with PBS and then lysed with 0.1% triton X-100.
The lysed cells were collected from each well and used to prepare serial dilutions. Each
dilution was plated in triplicate on BHI agar plates.

To determine the delivery of mazF mRNA to cells by Lm, DEME/F12 containing
100 µg/ml gentamicin was replaced by the same medium containing 10 µg/ml gentamicin.
The cells were then maintained at 37°C under 5% CO2 for 5 days.

Delivery of mazF mRNAs into HER-Positive Cells by Lm Cells
As discussed in Chapter 5, MazF proteins induce cell death in eukaryotic cells.
Hence, the viability assay and the presence of activated caspases were used as the indirect
evidence of delivery of mazF mRNA into cancer cells. Eukaryotic cells and the Lm cells
were prepared as described above. Consequent to 1hour post infection, cells from each well
were trypsinized and dispensed into 96-well plates at 2.5x104 cells/ml. To eliminate noninternalized bacteria, 10 µg/ml gentamycin was added into each well. The viability of
eukaryotic cells was analyzed using MTT assay (Promega, USA) in accordance with the
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manufacture’s protocol. For this assay, the medium was removed from each well , and the
cells were washed with PBS once. The next step was the addition of 100 µl of MTT
solution, followed by incubating the plate at 37°C under 5% CO2 for 2-4 hours. The
viability of cells was determined based on the absorption of the reagent at 490 nm. The
caspase activity was evaluated by caspase -3 and -7 assay (Promega, USA) according to
the manufacturer’s instructions.
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Results
Construction of a T7 Transcription System for mazF mRNA in
L. monocytogenes
The ability of cancer cells to develop adaptation against various molecular
treatments such as DNA has remained the biggest obstacle in cancer therapy. However,
transient delivery of mRNAs has been a promising approach to treat cancer with a low
chance of resistance. It has been shown that L. monocytogenes, as a vector, has a great
potential to deliver therapeutic mRNAs into cellular cytosols that stems from the L.
monocytogenes’ ability to escape from the vacuoles and enter the cytosol where the
therapeutic mRNAs can be released from vectors and expressed in the cells [63]. Schoen
et al. designed a T7 expression plasmid system for GFP mRNAs delivery by L.
monocytogenes in Caco-2 cells [63]. This system contains two plasmids: pCSA1 and
pCSB1. In this research, pCSB1 was genetically engineered to generate mazF mRNA and
used to transfer mRNAs to SKBR-3, a breast cancer cell line overexpressing HER. The
constructs are explained in detail below.

Plasmid pCSA1: Plasmid pCSA1 carries the T7 RNA polymerase gene (polT7) and the
lysin gene from phage A118 (ply 118) under the control of a listerial promoter, actA
promoter (PactA). For maintenance and expression purposes, this plasmid is equipped with
two sets of replication origins from Gram-positive bacteria (repD and repE) and Gramnegative bacteria (oriE1). In addition, the erythromycin resistance gene and the gene for
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the tryptophanyl-tRNA synthetase (trpS) in the plasmid secure the presence of the plasmid
in cells [63] (Figure 4.1) .

Figure 4.1. pCSA1 map. pCSA1 carries the T7 polymerase gene and suicide gene

Plasmid pCSB-mazF-kan: This plasmid is supplied with the origin of replications
for Gram-positive bacteria (repU) from plasmid pBC16 and for Gram-negative bacteria
(colE1). This plasmid carries a mutated variant of the bacteriophage T7 promoter f10
(PT7), followed by a transcriptional terminator (T T7). Since mRNAs generated by bacteria
are cap- and poly-A -less, the internal ribosomal entry site of the encephalomyocarditis
virus (IRES EMCV) was placed downstream of T7 promoter [63].
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In this research, an ACA-less mazF fragment from pBApo (Takara Bio., USA) was
placed downstream of the IRES on pCSB1 vector through the overlapping PCR technique.
For this purpose, two sets of primers were designed to amplify the ACA-less mazF
fragment and pCSB1 with appropriate overlaps. The construct was assembled by NEB
DNA Polymerases ligating the insert and the vector together. Since the L. monocytogenes
strain used in this study is already resistant to tetracycline, this antibiotic marker was
replaced by a kanamycin gene through overlapping PCR as explained above (Figure 4.2).
The genetic modifications of pCNB-mz-Kn were conducted in E. coli DH10 B host, and
the final construct and pCSA1 were electroporated into L. monocytogenes.
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Figure 4.2. pCNB-mz-kn, carries mazF gene under the control of T7 promoter
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Interaction of Protein A with Anti-HER Antibodies for Bacterial Coating
To generate and deliver mazF mRNA into cancer cells, an attenuated L.
monocytogenes lacking internalin A and B was recruited. This strain was engineered to
express cell wall-anchored S. aureus protein A (SPA). The functionalization of bacteria
occurs through binding of the Fc fragment of antibodies to protein A anchored on L.
monocytogenes cell walls [168]. As described by Hesig et al., the SPA gene is placed under
the control of listeriolysin (hly) promoter (Phly). This gene contains the sequence of all five
Fc binding domains and the LPXTG motif for sortase-dependent anchoring of the SPA
protein to peptidoglycan. The genotype of this attenuated strain is ΔtrpS,
aroA,inlA/B,int::Phly-spa × pFlo-trpS and termed Lm-spa+. The Lm-spa- strain has the
identical genotype (ΔtrpS, aroA,inlA/B,int::Phly-spa × pFlo-trpS) to Lm-spa+ [168],
except that it does not carry the SPA gene, and this strain was used as the negative control
in this research.

The functionalized SPA-mediated Lm-spa+ cells with antibodies were evaluated
by immunofluorescence microscopy. For this purpose, 1x109 CFU/ml of Lm-spa+ or Lmspa- cells were incubated with 4 μg of human ErbB2/HER2 Alexa Fluor 488-conjugated
antibody for 1 hour at 23C under vigorous shaking. Subsequently, the bacterial cells were
washed with PBS, and unbonded antibodies were removed. As shown in Figure 4.3, Lmspa+ strains generated strong fluorescence signals, while Lm-spa- was not detectable under
the immunofluorescence microscopy. Therefore, the comparison of Lm-spa+ and Lm-spa-

114

strains implies that Lm-spa+ produce SPA on their cells, and also the bacterial cells can be
efficiently functionalized with antibodies.

a. Lm-spa+

b. Lm-spa-

Figure 4.3. The functionalized Lm-spa+ and Lm-spa- with human ErbB2/HER2 Alexa Fluor 488conjugated antibody. a) Lm-spa+, and b) Lm-spa-

Immunolabeling of SKBR3 Cells with Anti-HER 2 Antibodies
The overexpression of human epidermal growth factor receptor 2 (HER2) is one of
the important biomarkers in several aggressive human cancers, such as stomach, ovary,
uterine serous endometrial carcinoma, colon, bladder, lung, uterine cervix, head and neck,
and esophagus. This receptor has been reported to be overexpressed in 15-30% of invasive
breast cancers. SKBR3 is a breast cancer cell line overexpressing HER2 that is derived
from mammary gland/breast and metastatic site (ATCC website). To analyze this
morphological feature of SKBR3 cells, 8x104 cells were seeded in a chamber slide 24 hours
prior to the immunolabeling process. The cells were incubated with human ErbB2/Her2
Alexa Fluor 488-conjugated Antibody for one hour at cultural condition. Subsequent to
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removing unbound antibodies, the cells were visualized under the immunofluorescence
microscopy (Figure 4.4). As the results showed, SKBR3 cells overexpressed HER2
receptors with high affinity to the ErbB2/Her2 antibody.

b. SKBR3 labeled with Mouse IgG2

a. SKBR3 labeled with ErbB2/HER2
Alexa Fluor® 488-conjugated Antibody

Alexa Fluor® 488-conjugated isotype control

Figure 4.4. Immunofluorescence staining SKBR3 cells with an anti-HER antibody

Internalization of Anti-HER Functionalized Lm Cells into Eukaryotic Cells
in Vitro
Invasion and internalization of L. monocytogenes into non-phagocytic mammalian
cells are mediated by two surface proteins known as InlA and InlB. The deletion of inlAB
has been reported to drastically attenuate listerial entry into the non-phagocytic hosts. Lmspa+ is an attenuated L. monocytogenes strain that is inlAB deficient. However, it has been
shown that the internalization of this strain can be restored through antibody-mediated cell
targeting approaches [170]. When this attenuated strain enters the cells, it shows an

116

identical behavior to the wildtype to escape the vacuole and replicate in the cytosol [168].
In this study, Lm-spa+ was recruited to deliver mazF mRNA exclusively into cancer cells.
For improving the efficiency of this delivery system, antibody-mediated targeting was
optimized and discussed below.

The Impact of Bacterial Density on Antibody-Mediated Internalization
The impact of bacterial density on antibody-mediated targeting was analyzed by
inoculation of SKBR3 cells with different bacterial concentrations in vitro. For this
purpose, 3x105 cells/well were seeded in 12-well plates for 48 hours. Consequently, the
cells were infected with the functionalized Lm-spa+ at 10, 50, 100, and 200 MOI
(Multiplicity of Infection), i.e., the bacteria to SKBR3 ratio, for 1 hour. Non-coated Lmspa+ was used as the negative control to confirm that the internalization of bacterial cells
was indeed mediated by anti-HER antibodies. To remove the exterior bacterial cells, the
infected cells were washed 5 times with PBS and then subjected to a lysing process. The
lysate was plated on BHI plates and the CFU/ml was calculated for each MOI (Figure 4.5).
As exhibited in Figure 5, the increment of bacterial density leads to an increase in the
bacterial internalization in an antibody-independent manner. According to the CFU/ml
value, the infection of cells with an MOI of 100 had the highest internalization compared
to the non-coated bacteria. The antibody-meditated internalization rate of bacteria was
calculated by dividing the amount of coated by the amount of non-coated bacteria, as
previously described by Heisig [171]. Our results indicated that applying an MOI of 400
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led to a drastically reduced infection rate. Thus, an MOI of 100 was applied for subsequent
experiments.
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Figure 4.5. Infection of SKBR3 cells with various concentrations of functionalized bacteria. The difference
was considered as statistically significant if P< 0.05 ( ). NS: Not Significant.

Internalization of functionalized Lm into SKBR3 and 4T1 Cell Lines

119

To validate the specificity of antibody-mediated of targeting cells, the Lm-spa+
cells coated with Human ErbB2/Her2 Alexa Fluor® 488-conjugated Antibody (R&D
system, USA) was used to infect SKBR3 cells. Lm-spa+ cells coated with Mouse IgG2
Alexa Fluor® 488-conjugated isotype (R&D system, USA) was used as a negative control.
Subsequent to infection of SKBR3 cells with coated bacteria cells, cancer cells were lysed
in Triton 10X and plated in BHI medium. As shown in Figure 4.6, the density of
internalized bacteria in SKBR3 was almost two logs higher in comparison to the negative
control. However, it was observed that the bacteria coated with Human ErbB2/HER2
Alexa Fluor® 488-conjugated antibody were able to enter 4T1 cells. Therefore, in
subsequent experiments, bacteria were only coated with Anti-HER2 (Trastuzumab)
Humanized Antibody (Bio Vision, USA).

120

10000000

1000000

CFU/ml

100000

10000

1000

100

10

1

Lm-spa+ cells coated with anti
HER antibody

Lm-spa+ coated with Mouse
IgG2

Figure 4.6. The infection of SKBR3 with Lm cells coated with Human ErbB2/HER2 Alexa Fluor® 488conjugated. Bacterial cells with Mouse IgG2 were used as the negative control.

The Lm-spa+ cells coated with Anti-HER2 (Trastuzumab) Humanized Antibody
were utilized to infect 4T1, the mouse mammary gland cells, and SKBR3, the breast cancer
cells, in vitro. In contrast to SKBR3, 4T1 cells are known as HER negative cells and were
used as the negative control in these experiments. The cell lines were inoculated with 100
MOI Lm-spa+ for 1 hour post infection. The CFUs/ml of the internalized bacteria are
depicted in Figure 4.7.
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Figure 4.7. The infection of HER positive and negative cell lines with Lm-spa+ in vitro.

According to Figure 4.7, the internalization of Lm-spa+ into cells follows antibodydependent manners. In contrast to 4T1 cells, the internalization of bacteria increased
approximately 1000-fold in SKBR3 cells.
These results are consistent with Heisig’s findings, which indicates that the
internalization of Lm-spa+ depends on the functionalization of bacterial cells with
antibodies that correspond to specific receptors on host cells (Heisig, 2009).

Toxicity of the Bacterial Vectors in SKBR3 Cells
In the current project, Lm-spa+ was employed to specifically deliver mazF mRNA
into cancer cells. Lm-spa+ was equipped with a suicide gene which destroys the bacterial
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cells in the host cytosols. As discussed in previous sections, the MazF protein has a great
potential to induce death in transfected cells. To contribute the induced cell death
exclusively to the translation of the delivered mazF mRNA, the influence of the vector
harbouring pCSA1 on cell viability was investigated in vitro (Figure 4.8). According to our
results, the Lm-spa+ strain as the vector does not show a significant impact on cell viability.
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Figure 4.8. The influence of coated bacteria on cell viability. The difference was considered as statistically
significant if P< 0.05 ( ). NS: Not Significant.

Bacterial-Mediated Delivery of mazF mRNA into SKBR3
Induction of cell death in SKBR3 by mazF mRNA
MazF protein, a bacterial ribonuclease, has a capability to cleave mRNAs at ACA
sequences. Degradation of mRNAs followed by inhibition of protein synthesis triggers a
lethal process in cells. In prior sections, the toxic effect of mazF mRNA on different cell
lines, i.e., MCF7, AGS, HT29, and HEK298 was shown. To validate the bacterial protein
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activity, SKBR3 cells were transfected with mazF mRNA, and induction of cell death was
analyzed (Figure 4.9). Similar to other cell lines, SKBR3 was susceptible to MazF protein
expression, leading to reduced viability of the transfected cells.
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Figure 4.9. The induction of death in SKBR3 cells by mazF mRNA. The difference was considered as
statistically significant if P< 0.05 ( ). NS: Not Significant.

Lm-spa+-mediated delivery of mazF mRNA into SKBR3

The emergence of bacterial therapy has opened a new window to fighting cancer.
Exploitation of bacteria to hone in on the tumors, application of bacterial toxins as cancer

124

treatments, and the ability of bacteria to deliver a gene into tumors are examples of bacterial
therapeutic approaches in the cancer field. The unique capability of L. monocytogenes to
enter the host’s cytosols has made this bacterium a suitable candidate for delivery of
therapeutic mRNAs into cells. In this investigation, Lm cells were transformed with a T7
transcription system for mazF mRNA delivery. The transformed bacteria were utilized to
infect SKBR3 for 1 hour. The infected cells were treated with gentamicin for another hour
and reseeded in 96-well plates. The expression of MazF in cells was measured through cell
viability and caspase activities. If mazF mRNA is synthesized and delivered into cancer
cells, the viability of the cells is expected to drop, while the caspase activity would increase.

The viability of SKBR3 and 4T1 cells infected by L. monocytogenes harboring
mazF fragment was depicted in Figure 4.10. The Lm-spa+ strain was used as the negative
control. Our results showed that the infection of cells with the functionalized Lm-spa+
carrying mazF solely decreased the viability of transfected cells, while no significant
cytotoxic effects in 4T1 were recorded.
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Figure 4.10. The impact of mazF delivered into SKBR3 and T4 cells. The difference was considered as
statistically significant if P< 0.05 ( ). NS: Not Significant.
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Figure 4.11, the activity of caspase was monitored for 48 hours post infection. The

activity of caspase -3 and -7 in SKBR3 cells infected with functionalized Lm-spa+ was
higher in comparison to other controls, and this activity increased 48 hours post infection.
These results indicated that attenuated L. monocytogenes expressing protein A can be
effectively functionalized with a target-specific antibody and employed for mRNA
delivery purposes. In this investigation, bacteria-mediated delivery of mazF mRNA was
developed for the first time.
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Figure 4.11. Detection of caspase -3 and -7 activity in cells infected with Lm-spa+ and Lm-spa-

Discussion
Gene delivery has been a promising route to treat or alleviate severe diseases such
as cancer and HIV [62]. Over the past few decades, the accumulation of knowledge and
advances in molecular technology have led to the development of various vectors for gene
delivery purposes. However, the application of the designed viral and non-viral vectors has
been constrained by several limitations, such as the lack of specificities and the toxic
impacts of vectors on host cells. Recently, the utilization of bacteria, due to their natural
abilities to identify and colonize tumors, for gene delivery purposes has been a focus in the
cancer field. Invasion of tumors, bacterial vaccines, bacterial toxins with anticancer
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activities, and gene delivery vectors are examples of strategies developed in the application
of bacteria against cancer [53].

L. monocytogenes is a versatile vector in gene delivery. The ability of this bacterium
to deliver DNA plasmid into macrophage cell lines was reported by Dietrich et al [70].
However, this bacterial delivery system has faced several challenges, such as the low
expression efficacy in non-dividing cells due to the need for plasmid translocation to the
cell nucleus. Integration of plasmid DNA into the host genome was another drawback of
this system, as reported by Dietrich et al [70]. To overcome these challenges, an L.
monocytogenes-mediated RNA delivery system was designed by Schoen et al., in which
GFP mRNAs were generated and transferred into phagocytic cells by L. monocytogenes
[63]. Recently, Heisig et al. described an attenuated L. monocytogenes that expresses the
S. aureus protein A on the cell walls. The attenuation of the bacteria stems from the deletion
of internalin A and B, the cell wall proteins that play important roles in invasion and
internalization of host cells. As reported previously, the anchored SPAs on the cell wall of
L. monocytogenes have the affinity to bind to the Fc part of antibodies, and the bacterial
internalization occurs through the interaction of antibodies with the corresponding
receptors (or other ligands) exposed on the surface of target cells [168]. In this research,
we utilized this attenuated vector to deliver mazF mRNA into cancer cells in an antibodydependent manner. In order to increase the safety profile of the attenuated bacteria, we
equipped the vector with a suicide gene to degrade the bacteria and release the therapeutic
products once the bacteria are inside the host cytosol. In this research, this attenuated L.
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monocytogenes was utilized to deliver a therapeutic mRNA into cancer cells for the first
time.

MazF is a bacterial toxin that can degrade mRNAs at ACA sequences and block
protein synthesis in bacterial and mammalian cells [143, 172]. As shown in Chapter 3,
MazF has the capability to trigger apoptosis in MCF7 cells, which are naturally resistant to
apoptosis, and induce cell death in two types of aggressive cancer cell lines, AGS and
HT29. The invasion and aggressiveness of these cell lines were reported to be related to
long non-coding RNAs (lnRNAs) containing several ACA codons in their sequences.
These lnRNAs might be potential targets for the MazF protein. Therefore, according to our
results, MazF can be confirmed as a potential and novel treatment against cancer. However,
the MazF protein is a non-specific ribonuclease, and the application of MazF in cancer
therapy demands the development of a delivery system with high specificity for cancer
cells.

In this study, we developed a bacterial delivery system for the MazF protein to
exclusively deliver mazF mRNA into cancer cells. To this end, a T7 delivery system
containing two plasmids, pCSA1 and pCNB-mz-kan, was developed to generate mazF
mRNA inside bacterial cells. In this system, pCSA1 carries T7 polymerase and the lysin
gene from phage A118 (ply 118), placed under the control of a listerial promoter, actA
promoter (PactA). In pCNB-mz-kn, the mazF fragment was inserted downstream of the
IRES, the internal ribosomal entry site of the encephalomyocarditis virus (IRES EMCV).
Since mazF mRNAs are cap-less and polyA-less mRNAs, the IRES can secure the mRNA
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integrity and enhance the translation of mazF mRNA in targeted cells. Because mazF was
inserted as the ribosome-binding-site-less-fragment, mazF mRNA was not translated in
bacterial cells. This T7 binary plasmid system was electroporated into an attenuated L.
monocytogenes that was InlA- and InlB- deficient and expressed SPA anchored to the cell
wall (Lm-spa+). Consequently, the bacterial vector was functionalized by Anti-HER2
(Trastuzumab) humanized antibody and employed to infect the breast cancer SKBR3 line
in vitro. The Anti-HER2 antibody enables the bacterial vector to exclusively target cells
overexpressing the cell surface receptors HER2/neu.

Lm-spa+ was designed to express anchored SPA on its cell walls. In order to
validate this feature of Lm-spa+, the bacterial cells were incubated with human
ErbB2/HER2 Alexa Fluor 488-conjugated antibody. The interaction of the antibody with
SPA was investigated under immunofluorescence microscopy. The comparison of Lmspa+ with Lm-spa-,which does not express protein A, implies that the interaction of the
applied antibodies with bacterial cells depends on the presence of protein A on bacteria
cell walls. This result was in agreement with the findings of Heisig [171].

The

specificity

of

antibody-receptor

interaction

was

investigated

by

immunostaining SKBR3 overexpressing HER2 with ErbB2/HER2 Alexa Fluor 488conjugated Antibody and the antibody isotype as the negative control. Our results validated
that the overexpression of HER2 receptors on SKBR3 cell surfaces resulted in a high
affinity to ErbB2/HER2 antibodies.
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The antibody-mediated internalization of attenuated Lm-spa+ was examined
through the infection of SKBR3 (HER2-positive) and 4T1 (HER2-negative) cells with Lmspa+. Our results showed that bacteria entered the cells in an antibody-dependent manner,
and the internalization of functionalized bacteria in SKBR3 was 3 logarithmic magnitudes
higher than in 4T1. The internalization of the coated bacteria was also 2 logarithmic
magnitudes higher than non-coated bacteria. These results imply that the internalization of
this bacterial strain depends on the presence of protein A on bacterial cell walls and the
interaction of the linked antibody to SPA with corresponding receptors on cell surfaces. In
this experiment, the expression of SPA was induced by the supplement of the bacterial
medium with 1% XAD. Our observation showed that bacteria growing in medium lacking
XAD failed to express SPA. However, Heisig reported that internalization of bacteria
without artificially-activated prfA by XAD was significantly reduced [171].

The density of bacteria is another important element that influences the specificity
of bacterial internalization in cells. To optimize the antibody-mediated cell entry, SKBR3
cells were infected with different concentrations of bacterial cells. Our observations
indicated that increasing the bacteria MOI from 100 to 400 led to antibody-independent
entry in cells. The incubation of cells with bacteria for 2 hours or more also caused
antibody-independent internalization (data not shown). However, Heisig suggested that a
two hour-incubation enhances bacterial internalization [171].

In this research, Lm-spa+ was employed to deliver mazF mRNA into SKBR3 cells.
In order to contribute the MazF-mediated cell death exclusively to translation of the
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delivered mazF mRNA, the influence of the vector harboring pCSA1 on cell viability was
investigated in vitro. As shown in Figure 4.8, the vector does not have a significant
cytotoxicity to SKBR3 cells.

The ability of Lm-spa+ to carry the T7 transcription delivery system for mazF mRNA was
validated by inoculating SKBR3 cells with Lm-spa+ equipped with the mazF fragment.
Our results showed that the vector can exclusively deliver mazF mRNAs into targeted cells.
As we reported in Chapter 3, MazF can induce apoptosis in cancer cells. The activity of
caspase is one of the markers of apoptosis in eukaryote cells. As shown in
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Figure 4.11, the infected cells with functionalized bacteria exhibit higher caspase inactivity
48 hours post transfections. This vector was previously utilized for the delivery of plasmids
encoding prodrug-converting enzymes into 4T1- HER2 cells. As a proof of concept, it was
reported to have only 25% cytotoxicity in transfected cells. Therefore, further
optimizations for prodrug delivery purposes were suggested by Heisig [171]. Lm-spa+was
previously used for delivery of plasmids encoding prodrug-converting enzymes into 4T1HER2 cells, the delivery rate was observed to be low, and only 25% cytotoxicity in
transfected cells was reported [171]. Heisig et al. investigated the internalization of Lmspa+ into xenograft mouse tumors. Their results showed that in contrast to in vitro
experiments, the internalization of bacteria depended on crosslinking of the antibody to
SPA on the surface of live bacteria. After crosslinking, the bacterial count in the tumors
was significantly increased in comparison to non-coated bacteria [168].
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CHAPTER FIVE
5.

Conclusion

Cancer remains the second leading cause of mortality and morbidity worldwide.
Besides the side effects and limitations of traditional therapies, its natural abilities to
develop adaptation against medical treatments have made cancer one of the main concerns
of recent centuries. Therefore, the introduction of novel therapies with high safety profiles
is strongly demanded. Recently, ribonucleases with anticancer activities have opened a
new avenue to treat cancer [79]. Ribonucleases can inhibit protein synthesis at transcription
and translation stages. Thus, development of resistance to these small proteins seems to be
challenging for cancer cells. In recent years, many ribonucleases with anticancer activities
have been identified in both eukaryotic and prokaryotic cells. However, within a short
period, it became evident that due to their instability, the lack of cytotoxic or cytostatic
activity, and the presence of ribonuclease inhibitors within cells, some specific
ribonucleases are weak candidates for cancer therapy applications [130]. Therefore, finding
stable ribonucleases with anticancer activity could be a promising treatment against this
lethal disease.

MazF is a small, 12kDa, and stable ribonuclease in bacterial cells that digests
mRNAs, tRNA, and rRNA at ACA sequences. Under normal conditions, MazE, a bacterial
antitoxin, binds to two MazF proteins and neutralizes their lethal functions. Under harsh
conditions, MazE is degraded by ATP-dependent proteases, while the released MazF
arrests cell proliferation and induces death within bacterial cells [131]. It has been reported
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that the expression of the mazEF locus is inhibited during stressful conditions [76]. One of
the reasons for this inhibition might stem from the ability of the MazF protein to cleave its
mRNAs at ACA sequences. To avoid the degradation of mazF mRNAs in cells, we used
an ACA-less mazF fragment for our experiments in this research. To validate that ACAless mazF will be expressed in the cells and the products have the same abilities and
functions as the wild type, a pBAD-mazF construct was designed and electroporated into
bacterial cells. In this construct, ACA-less mazF was inserted under the control of a
stringent and inducible promoter, PBAD. Our results exhibited that following the induction
of the PBAD promoter with arabinose, the viability of bacterial cells reduced drastically.
Over the 6 hours post induction, the surviving populations showed a 6-log reduction in
comparison to the control strain. The surviving cells also generated small colonies. These
results suggested that ACA-less mazF can be overexpressed, and the products can remain
lethal in bacterial cells.

Ribonucleases, antibiotics, bacterial toxins, and viruses block protein synthesis
leading to the onset of apoptosis in mammalian cells [143]. Shimazu et al. showed that
MazF could halt the growth of T-REx-293 cells, a human kidney cell line, and induce
apoptosis. Although the exact mechanism remains unknown, it seems that the MazFmediated apoptosis depends on the presence of BAK in cells [143]. The injection of mazF
plasmid DNA into tumors developed by T-REx-293 was unable to stop the progression of
tumors in 4 out of 8 mice. Further investigation showed that MazF proteins were absent in
tumors shortly after the injections. The lack of continuous expression of MazF in tumors,
degradation, and the incidence of mutations in mazF gene might be the potential reasons
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for the failure of MazF proteins to halt tumor growth and progression [172]. To address
these challenges, we utilized ACA-mazF fragments that generate MazF resistance mRNAs.
In addition, the DNA delivery system does not seem to be a suitable approach to transfer
the mazF gene in tumors. Also, the occurrences of mutations in the mazF sequence led to
the deactivation of MazF in tumors. Therefore, we developed an mRNA delivery system
to transfer ACA-less mazF mRNA exclusively into cancer cells.

Since cancer is a heterogeneous group of diseases with various sensitivities to
different treatments, we first examined the impact of MazF proteins on the growth and
viability of three different cancer cell lines, i.e., MCF7, HT29, and AGS. These cell lines
were transfected with ACA-less mazF mRNAs, and the cells were evaluated for MazFmediated cell death [145, 146].

mRNA is an attractive candidate as a non-viral treatment in gene therapy. Unlike
DNA, mRNA is translated independently from the nucleus. However, in comparison to
DNA, RNA is less stable in cells. In this study, we analyzed the role of the main structural
elements of mRNAs in their stability and the translation efficiency in vitro. Our results
demonstrated that ACA-less mazF mRNA can be translated in both cap- and IRESdependent manners. We also synthesized GFP mRNA for IRES- or cap- dependent
translation as the controls for the experiments. Our results showed that capped GFP
mRNAs were translated in all cell lines, while IRES-GFP mRNA was only expressed in
AGS cells. Further investigations showed that mazF and GFP mRNA without the caps or
poly-As were not expressed in all transfected cell lines. Therefore, the protection of the 5′
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ends of mRNAs by either a cap or IRES sequence is associated with the stability and
expression of mRNAs in transfected cells. It has been reported that the incorporation of
modified nucleotides such as pseudouridine in IVT the mRNA structure can enhance
stability and boost the expression of the mRNAs in cells in comparison to other modified
nucleotides [141]. Our observations suggested that cap/IRES-dependency, a poly-A tail,
and modified/unmodified nucleotides played important roles in the efficient expression of
MazF proteins in transfected cell lines but is cell line-dependent.

In mammalian cells, the inhibition of protein synthesis triggers apoptosis and
eventually induces death [143]. In this research, we analyzed the impact of MazF proteins
on the inhibition of protein synthesis, induction of apoptosis, and death in MC7, AGS and
HT 29 cells. The synthesis of nascent proteins was measured in transfected cells with mazF
mRNAs. As explained in detail in Chapter 3, the expression of MazF led to significant
inhibition of protein translation in the examined cell lines. In addition, our data showed
that MazF proteins can induce death in the transfected cancer cell lines (Figure 3.5). In
order to confirm MazF-mediated apoptosis, the activation of caspase -3 and -7 (Figure 3.6)
and the presence of PARP as a biomarker of apoptosis were examined (Figure 3.8). Our
observations suggested that in the presence of MazF, the levels of caspase -3 and - 7
significantly increased, and apoptosis took place in the cells. These results confirm the
antiproliferative action and apoptotic ability of MazF in cancer cells. However, MazF is a
nonspecific ribonuclease that can induce death in both normal and tumor cells. Thus, the
application of MazF is dependent on efficient expression and delivery of MazF into tumors.
As described in Chapter 4, we developed and utilized a bacterial delivery system to
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exclusively deliver mazF mRNAs into cancer cells. For this purpose, a T7 delivery system
containing two plasmids, pCSA1 and pCNB-mz-kan, was developed to produce mazF
mRNAs inside the bacterial cells and deliver the mRNAs into cancer cells. To deliver the
T7 system, an attenuated L. monocytogenes that was InlA- and InlB- deficient and
expressed SPA anchored to the cell wall (Lm-spa+) was utilized to infect cancer cells. This
bacterial strain, due to displaying SPA on the cell walls, can be functionalized with cancerspecific antibodies. As discussed in Chapter 4 in detail, we functionalized the bacterial
vectors with anti-HER antibodies to transfer mazF mRNAs into SKBR3 cells that
overexpress HER receptors on their cell surfaces. Our results showed that consequent to
the infection of cells by functionalized bacterial vectors, caspase activities elevated in
SKBR3 cells 48 hours post-transfection. One advantage of this modular approach is that
the bacterial delivery system could be functionalized with different antibodies to target a
specific cancer or a group of cancer types.

In this research, for the first time, mazF mRNA was delivered into cancer cells
through an expression and delivery system. However, further experiments in vitro and in
vivo are required to verify and further improve the exclusive abilities of this system to
deliver therapeutic molecules into specific cancer cells. As a proof of concept, we
demonstrated that mazF mRNA can be translated in cancer cells in an IRES-dependent
translation manner. Here, mazF was placed downstream of an attenuated phage IRES.
Since various IRES sequences have been found in mammalian mRNAs [173], the
application of non-attenuated and mammalian IRES might enhance the translation.
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Several bacteria such as Salmonella have cancer-specific promoters in their genome
[174]. Utilization of such promoters in the development of Lm vectors could further
increase the specificity of this system. Due to the limited number of proven cancer-specific
antibodies, these systems might not apply to all cancer types. Thus, using such promoters
might overcome this limitation of the Lm delivery systems.

In bacterial cells, several mRNAs are reported to be resistant to MazF functions
[37]. Application of MazF against cancer cells and identification of MazF targets in cancer
cells might advance the current knowledge about mammalian mRNAs and particularly
pathogenic mRNA involved in tumor progression.
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